<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs - Nieto Estrada, VH - 2017 | Cochrane Library</title> <meta content="Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs - Nieto Estrada, VH - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009761.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs - Nieto Estrada, VH - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009761.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009761.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs" name="citation_title"/> <meta content="Víctor H Nieto Estrada" name="citation_author"/> <meta content="Fundacion Universitaria Sanitas, Colombia Clinic" name="citation_author_institution"/> <meta content="Daniel Molano Franco" name="citation_author"/> <meta content="Fundacion Universitaria de Ciencias de la Salud, Hospital de San José" name="citation_author_institution"/> <meta content="Roger David Medina" name="citation_author"/> <meta content="Fundación Universitaria de Ciencias de la Salud" name="citation_author_institution"/> <meta content="Alejandro G Gonzalez Garay" name="citation_author"/> <meta content="National Institute of Pediatrics" name="citation_author_institution"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="Ingrid Arevalo‐Rodriguez" name="citation_author"/> <meta content="inarev7@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009761.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009761.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009761.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009761.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetazolamide [adverse effects, *therapeutic use]; Altitude Sickness [complications, epidemiology, *prevention &amp; control]; Brain Edema [epidemiology, etiology, *prevention &amp; control]; Budesonide [*therapeutic use]; Carbonic Anhydrase Inhibitors [adverse effects, *therapeutic use]; Dexamethasone [adverse effects, *therapeutic use]; Glucocorticoids [*therapeutic use]; Hypertension, Pulmonary [epidemiology, *prevention &amp; control]; Paresthesia [chemically induced]; Publication Bias; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009761.pub2&amp;doi=10.1002/14651858.CD009761.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009761\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009761\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ms","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009761.pub2",title:"Interventions for preventing high altitude illness: Part 1. Commonly\\u2010used classes of drugs",firstPublishedDate:"Jun 27, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009761.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009761.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009761.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009761.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009761.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009761.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009761.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009761.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009761.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009761.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5010 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009761.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0246"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-sec-0240"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/appendices#CD009761-sec-0251"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/table_n/CD009761StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/table_n/CD009761StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0002">Víctor H Nieto Estrada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0003">Daniel Molano Franco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0004">Roger David Medina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0005">Alejandro G Gonzalez Garay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0006">Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information#CD009761-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Ingrid Arevalo‐Rodriguez</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information/en#CD009761-sec-0268">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009761.pub2">https://doi.org/10.1002/14651858.CD009761.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009761-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009761-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009761-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009761-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009761-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009761-abs-0001" lang="en"> <section id="CD009761-sec-0001"> <h3 class="title" id="CD009761-sec-0001">Background</h3> <p>High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres ( ˜ 8200 feet ). Acute hypoxia, acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude. In this review, the first in a series of three about preventive strategies for HAI, we assess the effectiveness of six of the most recommended classes of pharmacological interventions. </p> </section> <section id="CD009761-sec-0002"> <h3 class="title" id="CD009761-sec-0002">Objectives</h3> <p>To assess the clinical effectiveness and adverse events of commonly‐used pharmacological interventions for preventing acute HAI. </p> </section> <section id="CD009761-sec-0003"> <h3 class="title" id="CD009761-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), Embase (OVID), LILACS and trial registries in January 2017. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus‐based and free‐text terms to search. </p> </section> <section id="CD009761-sec-0004"> <h3 class="title" id="CD009761-sec-0004">Selection criteria</h3> <p>We included randomized‐controlled and cross‐over trials conducted in any setting where commonly‐used classes of drugs were used to prevent acute HAI. </p> </section> <section id="CD009761-sec-0005"> <h3 class="title" id="CD009761-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as expected by Cochrane.</p> </section> <section id="CD009761-sec-0006"> <h3 class="title" id="CD009761-sec-0006">Main results</h3> <p>We included 64 studies (78 references) and 4547 participants in this review, and classified 12 additional studies as ongoing. A further 12 studies await classification, as we were unable to obtain the full texts. Most of the studies were conducted in high altitude mountain areas, while the rest used low pressure (hypobaric) chambers to simulate altitude exposure. Twenty‐four trials provided the intervention between three and five days prior to the ascent, and 23 trials, between one and two days beforehand. Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level. Risks of bias were unclear for several domains, and a considerable number of studies did not report adverse events of the evaluated interventions. We found 26 comparisons, 15 of them comparing commonly‐used drugs versus placebo. We report results for the three most important comparisons: </p> <p><b>Acetazolamide versus placebo (28 parallel studies; 2345 participants)</b> </p> <p>The risk of AMS was reduced with acetazolamide (risk ratio (RR) 0.47, 95% confidence interval (CI) 0.39 to 0.56; I<sup>2</sup> = 0%; 16 studies; 2301 participants; moderate quality of evidence). No events of HAPE were reported and only one event of HACE (RR 0.32, 95% CI 0.01 to 7.48; 6 parallel studies; 1126 participants; moderate quality of evidence). Few studies reported side effects for this comparison, and they showed an increase in the risk of paraesthesia with the intake of acetazolamide (RR 5.53, 95% CI 2.81 to 10.88, I<sup>2</sup> = 60%; 5 studies, 789 participants; low quality of evidence). </p> <p><b>Budenoside versus placebo (2 parallel studies; 132 participants)</b> </p> <p>Data on budenoside showed a reduction in the incidence of AMS compared with placebo (RR 0.37, 95% CI 0.23 to 0.61; I<sup>2</sup> = 0%; 2 studies, 132 participants; low quality of evidence). Studies included did not report events of HAPE or HACE, and they did not find side effects (low quality of evidence). </p> <p><b>Dexamethasone versus placebo (7 parallel studies; 205 participants)</b> </p> <p>For dexamethasone, the data did not show benefits at any dosage (RR 0.60, 95% CI 0.36 to 1.00; I2 = 39%; 4 trials, 176 participants; low quality of evidence). Included studies did not report events of HAPE or HACE, and we rated the evidence about adverse events as of very low quality. </p> </section> <section id="CD009761-sec-0007"> <h3 class="title" id="CD009761-sec-0007">Authors' conclusions</h3> <p>Our assessment of the most commonly‐used pharmacological interventions suggests that acetazolamide is an effective pharmacological agent to prevent acute HAI in dosages of 250 to 750 mg/day. This information is based on evidence of moderate quality. Acetazolamide is associated with an increased risk of paraesthesia, although there are few reports about other adverse events from the available evidence. The clinical benefits and harms of other pharmacological interventions such as ibuprofen, budenoside and dexamethasone are unclear. Large multicentre studies are needed for most of the pharmacological agents evaluated in this review, to evaluate their effectiveness and safety. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009761-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009761-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009761-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009761-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009761-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009761-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009761-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009761-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009761-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009761-abs-0004" lang="en"> <h3>Drugs commonly‐used for preventing high altitude illness</h3> <p><b>Background</b> </p> <p>High altitude illness (HAI) is a term used to describe a group of brain and breathing conditions that can occur while travelling to altitudes above 2500 metres ( ˜ 8200 feet ). HAI is generally characterized by headache, nausea, vomiting and tiredness (often called acute mountain sickness), but may affect the brain or the lungs in different individuals. In this review, we assessed the most commonly‐used drugs to prevent the onset of this illness. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to January 2017. We included 64 studies related to six different types of drugs recommended for HAI prevention. Most of the studies were conducted in high altitude mountain areas, while the rest used low pressure (hypobaric) chambers to simulate altitude exposure. The participants' ages ranged between 16 and 65 years. Eleven studies included people at a high risk of this condition due to their history of HAI or other illnesses such as asthma. Twenty‐four trials provided the intervention between three and five days prior to the ascent, and 23 trials, between one and two days beforehand. Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level. In 23 of the included studies, the source of funding was unclear. Only 18 studies declared their possible conflicts of interests. We classed 24 more studies as still ongoing or waiting for assessment. </p> <p><b>Key results</b> </p> <p>Our findings suggest that acetazolamide is an effective treatment for the prevention of acute HAI in dosages of 250 to 750 mg/day, when this drug is compared to a placebo (i.e. a pill with no active agent). Most of the available information relates to the prevention of uncomplicated HAI (headache, nausea, vomiting and tiredness) rather than to more serious brain or lung problems. We also found that acetazolamide is associated with an increased risk of paraesthesia in the fingers (i.e. a sensation of tingling, tickling, pricking, or burning of the skin), although this outcome is not well reported in the available evidence. The benefits and harms of other drugs such as ibuprofen, budenoside and dexamethasone are unclear, due to the small number of studies. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence as moderate to very low. Several studies had quality shortcomings, including their use of small numbers of participants and a lack of reporting of important outcomes such as side effects. For most of the drugs covered by the studies, additional research is required to clarify their effectiveness and safety. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009761-sec-0246" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009761-sec-0246"></div> <h3 class="title" id="CD009761-sec-0247">Implications for practice</h3> <section id="CD009761-sec-0247"> <p>Our analysis suggests that acetazolamide, administered between three and five days prior to ascent, is an effective pharmacological agent to prevent acute altitude sickness in dosages of 250 to 750 mg/day. This information is based on evidence of moderate quality. Acetazolamide is associated with an increased risk of paraesthesia, which should be balanced against the suggested benefit. The clinical benefits and harms from other pharmacological interventions are unclear. There is little evidence relating to the prevention of HAPE and HACE, due to the low number of events reported. </p> </section> <h3 class="title" id="CD009761-sec-0248">Implications for research</h3> <section id="CD009761-sec-0248"> <p>There is a need for further high‐quality research in this area. Future studies should be adequately powered to assess the effectiveness of these agents for the prevention of more serious forms of AMS, in combination as well as single agents. The design of future trials might be improved by the following suggestions: </p> <p> <ol id="CD009761-list-0008"> <li> <p>Refining the clinical definition of AMS, HAPE and HACE.</p> </li> <li> <p>Improving the reporting of statistical data related to important results, in order to avoid missing data, including information about elevation where HAI occurs. </p> </li> <li> <p>Adding adverse events as an important endpoint in assessment of these preventive strategies.</p> </li> <li> <p>Comparing pharmacological agents against interventions of established effectiveness (such as acetazolamide). </p> </li> </ol> </p> <p>Finally, we suggest performing a network meta‐analysis of all interventions (pharmacological and non‐pharmacological) used for high altitude illness prevention, in order to determine which interventions are effective in avoiding the onset of new cases of this condition. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009761-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009761-sec-0029"></div> <div class="table" id="CD009761-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetazolamide compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acetazolamide compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> acetazolamide<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetazolamide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/> (94 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.39 to 0.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2301<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of high altitude pulmonary oedema (HAPE)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1138<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These trials reported no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of high altitude cerebral oedema (HACE)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> <br/> (0.01 to 7.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1126<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: Paresthesias‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>504 per 1000</b><br/> (256 to 992) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.53</b> (2.81 to 10.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>789<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: side effects‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>232 per 1000</b><br/> (144 to 374) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.19</b> <br/> (1.36 to 3.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to unclear selection, performance and detection bias in most of included studies. High risk of attrition bias in five studies.<br/> <sup>2</sup>Risk of bias downgraded (‐1) due to unclear selection, performance and detection bias. </p> <p><sup>3</sup> Risk of bias downgraded (‐2) due to unclear selection, performance and detection bias, as well as considerable heterogeneity (60%)<br/> <sup>4</sup>Risk of bias downgraded (‐2) due to high levels of attrition bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009761-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Budesonide compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> budenoside<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/> (139 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.37</b> <br/> (0.23 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude pulmonary oedema (HAPE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude cerebral oedema (HACE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: Side effects‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This trial reported no events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to high risk of performance bias in one out of two studies included.<br/> <sup>2</sup>Imprecision downgraded (‐1) due to insufficient sample size to determine whether there are differences or not between these two groups.<br/> <sup>3</sup>Risk of bias downgraded (‐1) due to high risk of performance bias.<br/> <sup>4</sup>Imprecision downgraded (‐2) due to insufficient sample size to determine whether there are differences or not between these two groups. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009761-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dexamethasone compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dexamethasone compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> dexamethasone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dexamethasone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b><br/> (162 to 449) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.36 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude pulmonary oedema (HAPE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude cerebral oedema (HACE)</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: General‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This trial reported no events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to unclear risk of selection, performance and detection bias in almost all studies included.<br/> <sup>2</sup>Imprecision downgraded (‐1) due to insufficient sample size to determine whether there are differences or not between these two groups.<br/> <sup>3</sup>Risk of bias downgraded (‐1) due to unclear risk of selection, performance and detection bias.<br/> <sup>4</sup>Imprecision downgraded (‐2) due to insufficient sample size to determine whether there are differences or not between these two groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009761-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009761-sec-0030"></div> <p>High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres ( ˜ 8200 feet). HAI is arbitrarily classified as high (1500 to 3500 metres ), very high (3500 to 5500 metres or ) and extreme (above 5500 metres ) (<a href="./references#CD009761-bbs2-0184" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [MEDLINE: 20808661] ">Paralikar 2010</a>). Because of the large number of people who ascend rapidly to between 2500 and 3500 m , high altitude illness is common in this height range (<a href="./references#CD009761-bbs2-0184" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [MEDLINE: 20808661] ">Paralikar 2010</a>). Although the proportion of oxygen remains unchanged at 20.93%, increases in altitude result in a lower partial pressure of oxygen in the inspired air (<a href="./references#CD009761-bbs2-0128" title="Anonymous . Mountain sickness. British Medical Journal1892;1(1633):829. ">Anonymous 1892</a>; <a href="./references#CD009761-bbs2-0206" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [MEDLINE: 19161909] ">Wilson 2009</a>). This reduction in the driving pressure of oxygen, along the oxygen cascade from the lungs to the tissues, can compromise the supply of oxygen to the tissues (<a href="./references#CD009761-bbs2-0206" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [MEDLINE: 19161909] ">Wilson 2009</a>), especially the cardiovascular and pulmonary systems (<a href="./references#CD009761-bbs2-0169" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. International Journal of Anesthesia2009;23(4):543‐53. [MEDLINE: 19921365] ">Leissner 2009</a>). The physiological responses to hypoxia and acclimatization related to HAI include hyperventilation (increased depth and rate of breathing), elevation of systemic blood pressure and tachycardia (elevations of heart rate) (<a href="./references#CD009761-bbs2-0169" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. International Journal of Anesthesia2009;23(4):543‐53. [MEDLINE: 19921365] ">Leissner 2009</a>; <a href="./references#CD009761-bbs2-0180" title="NaeijeR . Physiological adaptation of the cardiovascular system to high altitude. Progress in Cardiovascular Diseases2010;52(6):456‐66. [MEDLINE: 20417339] ">Naeije 2010</a>). However, in many instances these physiologic changes may be inadequate, such that the sojourn to altitude and the concomitant hypoxia are complicated by altitude‐associated medical illness (<a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>), which is also known as high altitude illness. </p> <section id="CD009761-sec-0031"> <h3 class="title" id="CD009761-sec-0031">Description of the condition</h3> <section id="CD009761-sec-0032"> <h4 class="title">High altitude illness (HAI)</h4> <p>There are two types of mountain sicknesses: acute mountain sickness (AMS) and chronic mountain sickness (CMS), also called Monge's disease (<a href="./references#CD009761-bbs2-0177" title="MongeC . Life in the Andes and chronic mountain sickness. Science1942;95(2456):79‐84. [MEDLINE: 17757318] ">Monge 1942</a>). Acute hypoxia, acute mountain sickness, high altitude cerebral oedema (HACE), high altitude pulmonary oedema (HAPE), cerebrovascular syndromes, peripheral oedema, retinopathy, thromboembolism, sleep disorders and periodic breathing, high altitude pharyngitis and bronchitis, ultraviolet exposure and keratitis (snow blindness), and exacerbation of pre‐existing illness are reported as medical problems potentially associated with high altitude ascent (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>; <a href="./references#CD009761-bbs2-0194" title="SchoeneRB . Illnesses at high altitude. Chest2008;134(2):402‐16. [MEDLINE: 18682459] ">Schoene 2008</a>). Factors such as the rate of ascent, the absolute change in altitude, and individual physiology are the primary determinants of whether HAI will develop or not (<a href="./references#CD009761-bbs2-0169" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. International Journal of Anesthesia2009;23(4):543‐53. [MEDLINE: 19921365] ">Leissner 2009</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>). The risk categories for acute mountain sickness are shown in <a href="./appendices#CD009761-sec-0252">Appendix 1</a> (<a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>). </p> <p>In the 19th century, Dr Daniel Vergara, a Mexican physiologist, pioneered the studies on high altitude physiology and the physiological and anatomical mechanisms of adaptation to high elevations. Forty years later, Dr Carlos Monge, a Peruvian physiologist, reported his ideas on this issue. The work of these pioneers was summarized early this century (<a href="./references#CD009761-bbs2-0190" title="Rodríguez de RomoAC . Daniel Vergara Lope and Carlos Monge Medrano: two pioneers of high altitude medicine. High Altitude Medicine &amp; Biology2002;3(3):299‐309. [MEDLINE: 12396886] ">Rodríguez de Romo 2002</a>). Both the physiology and pathophysiology of high altitude have recently been widely reviewed (<a href="./references#CD009761-bbs2-0135" title="BärtschP , GibbsJS . Effect of altitude on the heart and the lungs. Circulation2007;116(19):2191‐202. [MEDLINE: 17984389] ">Bärtsch 2007</a>; <a href="./references#CD009761-bbs2-0169" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. International Journal of Anesthesia2009;23(4):543‐53. [MEDLINE: 19921365] ">Leissner 2009</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>; <a href="./references#CD009761-bbs2-0184" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [MEDLINE: 20808661] ">Paralikar 2010</a>). In brief, these reviews confirm both the increase in respiratory rate and increase in haemoglobin concentration on exposure to a low oxygen pressure, and that such changes are often inadequate. They identify the rate of ascent, the absolute change in altitude and individual variation in physiology as the primary determinants of whether HAI will develop or not (<a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>). HAI is considered an important cause of mountain mortality (<a href="./references#CD009761-bbs2-0207" title="WindsorJS , FirthPG , GrocottMP , RodwayGW , MontgomeryHE . Mountain mortality: a review of deaths that occur during recreational activities in the mountains. Postgraduate Medical Journal2009;85(1004):316‐21. [PUBMED: 19528307] ">Windsor 2009</a>). </p> </section> <section id="CD009761-sec-0033"> <h4 class="title">Acute mountain sickness (AMS) or high altitude cerebral oedema (HACE)</h4> <p>AMS is a multisystem disorder with prominent neurological features characterized by headache, anorexia, nausea and sometimes vomiting, light‐headedness, insomnia, and fatigue (<a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>; <a href="./references#CD009761-bbs2-0169" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. International Journal of Anesthesia2009;23(4):543‐53. [MEDLINE: 19921365] ">Leissner 2009</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>). Headache is the most prevalent symptom of acute mountain sickness. In contrast, HACE is a potentially fatal neurologic disorder and it is characterized by altered consciousness or ataxia (<a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>; <a href="./references#CD009761-bbs2-0156" title="HackettPH , RoachRC . High altitude cerebral edema. High Altitude Medicine &amp; Biology2004;5(2):136‐46. [MEDLINE: 15265335] ">Hackett 2004</a>; <a href="./references#CD009761-bbs2-0163" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [MEDLINE: 20417340] ">Imray 2010</a>), or both, in an individual with AMS or high altitude pulmonary oedema (HAPE). If left untreated, HACE can result in death due to cerebral oedema (<a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>). HACE is widely viewed as the end stage of AMS and is normally preceded by symptoms of AMS (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>), which suggest a similar pathophysiologic process (<a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>; <a href="./references#CD009761-bbs2-0163" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [MEDLINE: 20417340] ">Imray 2010</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>). Both syndromes share a common pathophysiology linked by intracranial hypertension (<a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>; <a href="./references#CD009761-bbs2-0164" title="KallenbergK , BaileyDM , ChristS , MohrA , RoukensR , MenoldE , et al. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. Journal of Cerebral Blood Flow and Metabolism2007;27(5):1064‐71. [PUBMED: 17024110] ">Kallenberg 2007</a>; <a href="./references#CD009761-bbs2-0195" title="SchoonmanGG , SandorPS , NirkkoAC , LangeT , JaermannT , DydakU , et al. Hypoxia‐induced acute mountain sickness is associated with intracellular cerebral edema: a 3 T magnetic resonance imaging study. Journal of Cerebral Blood Flow and Metabolism2008;28(1):198‐206. [PUBMED: 17519973] ">Schoonman 2008</a>; <a href="./references#CD009761-bbs2-0206" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [MEDLINE: 19161909] ">Wilson 2009</a>). The severity of AMS can be scored using the Lake Louise Questionnaire, Environmental Symptoms Questionnaire, or by the use of a simple analogue scale (<a href="./references#CD009761-bbs2-0163" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [MEDLINE: 20417340] ">Imray 2010</a>). Headache is a very common symptom at altitude and some authors have suggested it could be viewed as a distinct clinical entity. </p> <p>The definition of AMS seems to be problematic, as it will vary greatly between studies. A Lake Louise Score higher than two (including headache) is not equivalent to a criterion score of 0.70 with AMS‐C (cerebral) from the Environmental Symptoms Questionnaire (<a href="./references#CD009761-bbs2-0175" title="MaggioriniM , MüllerA , HofstetterD , BärtschP , OelzO . Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviation, Space, and Environmental Medicine1998;69(12):1186‐92. [PUBMED: 9856545] ">Maggiorini 1998</a>). It has been suggested that a previous review came to an erroneous conclusion because they included a study which used the AMS‐R (respiratory) score for diagnosis of AMS. The value of the AMS‐R score is questionable for diagnosing AMS (<a href="./references#CD009761-bbs2-0142" title="DumontL , MardirosoffC , TramèrMR . Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ2000;321(7256):267‐72. [MEDLINE: 10915127] ">Dumont 2000</a>). Pathophysiology with a focus on the molecular basis of AMS and HACE has been widely described by <a href="./references#CD009761-bbs2-0129" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [MEDLINE: 19763397] ">Bailey 2009a</a>, and advances in the genetics, molecular mechanisms, and physiology that underpin them have been extensively described by <a href="./references#CD009761-bbs2-0206" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [MEDLINE: 19161909] ">Wilson 2009</a>. </p> <p>This review treats headache as a common and early symptom of AMS. Indeed, the exact definition of what constitutes AMS will vary when using different scoring systems and when interpreted by different authors. In this review we have taken care not to pool data inappropriately where the scoring systems used cannot be directly compared. </p> </section> <section id="CD009761-sec-0034"> <h4 class="title">High altitude pulmonary oedema (HAPE)</h4> <p>HAPE is a non‐cardiogenic pulmonary oedema (<a href="./references#CD009761-bbs2-0171" title='LuksAM . Do we have a "best practice" for treating high altitude pulmonary edema?. High Altitude Medicine &amp; Biology2008;9(2):111‐4. [MEDLINE: 18578641] '>Luks 2008a</a>; <a href="./references#CD009761-bbs2-0193" title="SchoeneRB . Unraveling the mechanism of high altitude pulmonary edema. High Altitude Medicine &amp; Biology2004;5(2):125‐35. [MEDLINE: 15265334] ">Schoene 2004</a>; <a href="./references#CD009761-bbs2-0198" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [MEDLINE: 19099331] ">Stream 2008</a>). It is characterized by cough, progressive dyspnoea with exertion, and decreased exercise tolerance, generally developing within two to four days after arrival at high altitude (<a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>; <a href="./references#CD009761-bbs2-0198" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [MEDLINE: 19099331] ">Stream 2008</a>). It is rare after one week of acclimatization at a particular altitude (<a href="./references#CD009761-bbs2-0176" title="MaggioriniM . Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):500‐6. [MEDLINE: 20417343] ">Maggiorini 2010</a>; <a href="./references#CD009761-bbs2-0182" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [MEDLINE: 20442648] ">Palmer 2010</a>). Hypoxia is the trigger that results in a complex cascade of events leading to HAPE (<a href="./references#CD009761-bbs2-0198" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [MEDLINE: 19099331] ">Stream 2008</a>). Essentially, HAPE is due to a "persistent imbalance between the forces that drive water into the airspace and the biologic mechanisms for its removal" (<a href="./references#CD009761-bbs2-0191" title="ScherrerU , RexhajE , JayetPY , AllemannY , SartoriC . New insights in the pathogenesis of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):485‐92. [MEDLINE: 20417341] ">Scherrer 2010</a>), with the hallmark of this condition being hypoxic pulmonary hypertension. The hypertension may be mediated by at least four mechanisms: defective pulmonary nitric oxide synthesis, exaggerated endothelin‐1 synthesis, exaggerated sympathetic activation, and a defect in alveolar transepithelial sodium transport (<a href="./references#CD009761-bbs2-0191" title="ScherrerU , RexhajE , JayetPY , AllemannY , SartoriC . New insights in the pathogenesis of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):485‐92. [MEDLINE: 20417341] ">Scherrer 2010</a>). An extensive review of pulmonary hypertension induced by HAI is reported by <a href="./references#CD009761-bbs2-0185" title="PashaMA , NewmanJH . High‐altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest2010;137 Suppl(6):13‐9. [MEDLINE: 20522576] ">Pasha 2010</a>. </p> </section> <section id="CD009761-sec-0035"> <h4 class="title">Epidemiology of acute HAI</h4> <p>It has been estimated that 84% of people who fly directly to 3860 m are affected by AMS (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>). The incidence of HACE and HAPE is much lower than for AMS, with estimates in the range of 0.1% to 4.0% (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>). The rate of ascent, altitude reached (especially the sleeping altitude), and individual susceptibility are the most important risk factors for the development of HAI (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0192" title="SchneiderM , BernaschD , WeymannJ , HolleR , BärtschP . Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Medicine and Science in Sports and Exercise2002;34(12):1886‐91. [PUBMED: 12471292] ">Schneider 2002</a>). Other risk factors are a history of HAI and permanent residence lower than 900 metres, exertion in children and adults (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>), obesity (<a href="./references#CD009761-bbs2-0187" title="Ri‐LiG , ChasePJ , WitkowskiS , WyrickBL , StoneJA , LevineBD , et al. Obesity: associations with acute mountain sickness. Annals of Internal Medicine2003;139(4):253‐7. [PUBMED: 12965980] ">Ri‐Li 2003</a>), and coronary heart disease (<a href="./references#CD009761-bbs2-0140" title="DehnertC , BärtschP . Can patients with coronary heart disease go to high altitude?. High Altitude Medicine &amp; Biology2010;11(3):183‐8. [PUBMED: 20919884] ">Dehnert 2010</a>). It is advisable that those with asthma be sure that their condition is well controlled before they undertake exertion at altitude (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>). </p> <p>See <a href="./appendices#CD009761-sec-0253">Appendix 2</a> for other medical terms. </p> </section> </section> <section id="CD009761-sec-0036"> <h3 class="title" id="CD009761-sec-0036">Description of the intervention</h3> <p>The risk of high altitude illness (HAI) begins with a non‐acclimatized person ascending to an altitude higher than 2500 metres (<a href="./references#CD009761-bbs2-0184" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [MEDLINE: 20808661] ">Paralikar 2010</a>). However, a susceptible individual may develop AMS at an intermediate altitude such as 2000 metres (<a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>). Several interventions to prevent HAI have been described, compiled, and published in guidelines and consensus statements (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>; <a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>). Interventions for HAI prevention can be classified as pharmacological and non‐pharmacological (<a href="./references#CD009761-bbs2-0133" title="BärtschP . Treatment of high altitude diseases without drugs. International Journal of Sports Medicine1992;13 Suppl 1:71‐4. [MEDLINE: 1483799] ">Bärtsch 1992</a>; <a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>; <a href="./references#CD009761-bbs2-0172" title="LuksAM , SwensonER . Medication and dosage considerations in the prophylaxis and treatment of high‐altitude illness. Chest2008;133(3):744‐55. [MEDLINE: 18321903] ">Luks 2008b</a>; <a href="./references#CD009761-bbs2-0208" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [MEDLINE: 18076343] ">Wright 2008</a>). The Committee to Advise on Tropical Medicine and Travel proposed a consensus for HAI in 2007, describing prevention and treatment approaches among several topics regarding this medical condition (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>). </p> <p>In 2014, the Wilderness Medical Society (WMS) published an update of their 2010 guidelines (<a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>), detailing prevention and treatment directives for HAI (AMS, HACE, HAPE). This guideline was developed by an expert panel that compiled and classified all available evidence on HAI prevention and treatment. Recommendations based on evidence, using American College of Chest Physicians strategies, were agreed upon. For AMS and HACE, the experts proposed a risk classification where low‐risk people are discarded for prevention interventions. For HAPE, pharmacological prophylaxis is recommended for those with a previous diagnosis of HAI (<a href="./references#CD009761-bbs2-0174" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness &amp; Environmental Medicine2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] ">Luks 2014</a>). However, the document does not include all of the most frequent and broadly‐described pharmacological interventions for prevention and treatment of HAI. The most commonly suggested interventions are summarized below. </p> <p> <ol id="CD009761-list-0001"> <li> <p><b>Carbonic anhydrase inhibitors</b>: acetazolamide and methazolamide (<a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0161" title="HussainMM , AslamM . Hypoxia and pulmonary acclimatisation at 4578 m altitude: the role of acetazolamide and dexamethasone. Journal of the Pakistan Medical Association2003;53(10):451‐8. [MEDLINE: 14696884] ">Hussain 2004</a>; <a href="./references#CD009761-bbs2-0200" title="SwensonE , TeppemaL . Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story. Journal of Applied Physiology2007;102(4):1305‐7. [MEDLINE: 17194729] ">Swenson 2007</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>; <a href="./references#CD009761-bbs2-0208" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [MEDLINE: 18076343] ">Wright 2008</a>). </p> </li> <li> <p><b>Steroids</b>: budenoside, prednisolone and dexamethasone (<a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>;<a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>). </p> </li> <li> <p><b>Bronchodilator drugs</b>: Include salmeterol, theophyline and montelukast (<a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a>; <a href="./references#CD009761-bbs2-0166" title="KleinsasserA , LoeckingerA . Are sildenafil and theophylline effective in the prevention of high‐altitude pulmonary edema?. Medical Hypotheses2002;59(2):223‐5. [MEDLINE: 12208214] ">Kleinsasser 2002</a>; <a href="./references#CD009761-bbs2-0208" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [MEDLINE: 18076343] ">Wright 2008</a>). </p> </li> <li> <p><b>Selective inhibitor of phosphodiesterase type 5</b> (PDE5): taladafil (<a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>) and sildenafil (<a href="./references#CD009761-bbs2-0131" title="BatesMG , ThompsonAA , BaillieJK . Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Current Opinion in Investigational Drugs2007;8(3):226‐31. [MEDLINE: 17408118] ">Bates 2007</a>; <a href="./references#CD009761-bbs2-0166" title="KleinsasserA , LoeckingerA . Are sildenafil and theophylline effective in the prevention of high‐altitude pulmonary edema?. Medical Hypotheses2002;59(2):223‐5. [MEDLINE: 12208214] ">Kleinsasser 2002</a>; <a href="./references#CD009761-bbs2-0188" title="RichaletJP , GratadourP , RobachP , PhamI , DéchauxM , Joncquiert‐LatarjetA , et al. Sildenafil inhibits altitude‐induced hypoxemia and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2005;171(3):275‐81. [MEDLINE: 15516532] ">Richalet 2005</a>). </p> </li> <li> <p><b>Calcium modulators</b>: Include nifedipine and flunarizine (<a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>). </p> </li> <li> <p><b>Non‐steroidal anti‐inflammatory drugs</b> (NSAIDs) and other analgesic: aspirin, carbasalate and ibuprofen (<a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>). </p> </li> </ol> </p> </section> <section id="CD009761-sec-0037"> <h3 class="title" id="CD009761-sec-0037">How the intervention might work</h3> <p>Extensive reviews of the pharmacotherapy of HAI have recently been published (<a href="./references#CD009761-bbs2-0176" title="MaggioriniM . Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):500‐6. [MEDLINE: 20417343] ">Maggiorini 2010</a>; <a href="./references#CD009761-bbs2-0208" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [MEDLINE: 18076343] ">Wright 2008</a>). Below is a list and brief description of the common agents that have so far been suggested. <a href="./appendices#CD009761-sec-0254">Appendix 3</a> provides more detail, and discusses the potential adverse effects of each agent. </p> <p> <ol id="CD009761-list-0002"> <li> <p>Carbonic anhydrase (CA) inhibitors (acetazolamide and methazolamide) generate inhibition of CA in the kidneys, resulting in increased bicarbonate excretion in the urine and metabolic acidoses. The result is an offsetting of hyperventilation‐induced respiratory alkalosis, allowing chemoreceptors to respond more fully to hypoxic stimuli at altitude (<a href="./references#CD009761-bbs2-0168" title="LeafDE , GoldfarbDS . Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. Journal of Applied Physiology2007;102(4):1313‐22. [MEDLINE: 17023566] ">Leaf 2007</a>). Acetazolamide can also cause pulmonary vasodilation unrelated to carbonic anhydrase inhibition (<a href="./references#CD009761-bbs2-0162" title="HöhneC , PickerodtPA , FrancisRC , BoemkeW , SwensonER . Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. American Journal of Physiology. Lung Cellular and Molecular Physiology2007;292(1):L178‐84. [PUBMED: 16936246] ">Höhne 2007</a>; <a href="./references#CD009761-bbs2-0199" title="SwensonER . Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respiratory Physiology &amp; Neurobiology2006;151(2‐3):209‐16. [PUBMED: 16376158] ">Swenson 2006</a>). </p> </li> <li> <p>Steroids (dexamethasone, budesonide and prednisolone): Hypoxia‐induced vasogenic oedema has been suggested as one of the major mechanisms responsible for development of AMS (<a href="./references#CD009761-bbs2-0155" title="HackettPH . High altitude cerebral edema and acute mountain sickness. A pathophysiology update. Advances in Experimental Medicine and Biology1999;474:23‐45. [PUBMED: 10634991] ">Hackett 1999</a>). Glucocorticoids blocks hypoxia‐induced endothelial dysfunction (<a href="./references#CD009761-bbs2-0178" title="MurataT , HoriM , SakamotoK , KarakiH , OzakiH . Dexamethasone blocks hypoxia‐induced endothelial dysfunction in organ‐cultured pulmonary arteries. American Journal of Respiratory and Critical Care Medicine2004;170(6):647‐55. [MEDLINE: 15184203] ">Murata 2004</a>; <a href="./references#CD009761-bbs2-0179" title="MurataT , SuzukiN , YamawakiH , SatoK , HoriM , KarakiH , et al. Dexamethasone prevents impairment of endothelium‐dependent relaxation in arteries cultured with fetal bovine serum. European Journal of Pharmacology2005;515(1‐3):134‐41. [MEDLINE: 15907323] ">Murata 2005</a>). </p> </li> <li> <p>Bronchodilators (salmeterol, theophylline or aminophylline, montelukast). The human beta‐2 adrenergic receptor (B2AR) has been found to play a very important role in the pathogenesis of HAPE, and salmeterol was found to have a high binding affinity with human B2AR (<a href="./references#CD009761-bbs2-0137" title="ChandramoorthiGD , PiramanayagamS , MarimuthuP . An insilico approach to high altitude pulmonary edema ‐ Molecular modeling of human beta2 adrenergic receptor and its interaction with salmeterol &amp; nifedipine. Journal of Molecular Modeling2008;14(9):849‐56. [MEDLINE: 18512086] ">Chandramoorthi 2008</a>). Furthermore, salmeterol enhances alveolar clearance by stimulating amiloride‐sensitive sodium (Na) channels (<a href="./references#CD009761-bbs2-0176" title="MaggioriniM . Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):500‐6. [MEDLINE: 20417343] ">Maggiorini 2010</a>). Non‐selective phosphodiesterase inhibitor (theophylline or aminophylline): anti‐hypoxia and antioxidation effects of aminophylline (<a href="./references#CD009761-bbs2-0209" title="YangB , WangGY , ChenB , QinRB , XiSL , ChenL . Anti‐hypoxia and anti‐oxidation effects of aminophylline on human with acute high‐altitude exposure. Chinese Medical Sciences Journal2007;22(1):62‐5. [PUBMED: 17441321] ">Yang 2007</a>) could be responsible for reducing periodic breathing, cerebral and pulmonary microvascular permeability, and pulmonary artery pressure (<a href="./references#CD009761-bbs2-0208" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [MEDLINE: 18076343] ">Wright 2008</a>). Montelukast is a leukotriene receptor antagonist (LTRA) that reduces the bronchoconstriction (<a href="./references#CD009761-bbs2-0203" title="TintingerGR , FeldmanC , TheronAJ , AndersonR . Montelukast: more than a cysteinyl leukotriene receptor antagonist?. Scientific World Journal2010;10:2403‐13. [PUBMED: 21170491] ">Tintinger 2010</a>). </p> </li> <li> <p>Selective inhibitors of phosphodiesterase type 5 (taladafil and sildenafil) induce overproduction of nitric oxide, which attenuates pulmonary vasoconstriction during acute hypoxia (<a href="./references#CD009761-bbs2-0181" title="OzakiM , KawashimaS , YamashitaT , OhashiY , RikitakeY , InoueN , et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension2001;37(2):322‐7. [MEDLINE: 11230292] ">Ozaki 2001</a>; <a href="./references#CD009761-bbs2-0211" title="ZhaoL , MasonNA , MorrellN , KojonazarovB , SadykovA , MaripovA , et al. Sildenafil inhibits hypoxia‐induced pulmonary hypertension. Circulation2001;104(4):424‐8. [MEDLINE: 11468204] ">Zhao 2001</a>). It causes a reduction in pulmonary hypertension. </p> </li> <li> <p>Calcium channel blockers (CCBs): calcium channel antagonists or calcium antagonists (nifedipine, flunarizine) are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels and reduce pulmonary vascular resistance (<a href="./references#CD009761-bbs2-0154" title="HackettPH , RoachRC , HartigGS , GreeneER , LevineBD . The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. International Journal of Sports Medicine1992;13 Suppl 1:68‐71. [MEDLINE: 1483798] ">Hackett 1992</a>), leading to a reduction of the pulmonary hypertension. </p> </li> <li> <p>Non‐steroidal anti‐inflammatory drugs (NSAIDs) and other analgesics (aspirin, ibuprofen, carbasalate): it is postulated that prostaglandin‐mediated increases in cerebral microvascular permeability may contribute to the pathophysiology of AMS, and treatment with prostaglandin synthesis inhibitors could reduce this response (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>). </p> </li> </ol> </p> <p>See <a href="./appendices#CD009761-sec-0254">Appendix 3</a> for adverse events of the pharmacological interventions. </p> </section> <section id="CD009761-sec-0038"> <h3 class="title" id="CD009761-sec-0038">Why it is important to do this review</h3> <p>It is important to conduct this systematic review for many reasons. First, many people all over the world travel to recreational areas located at high altitudes, putting themselves at increased risk of developing acute HAI. HAI may be severe and life‐threatening, so effective prevention is likely to be of great value both to these visitors to high‐altitude areas, and to those responsible for their treatment and rescue when required. At the other end of the spectrum, reliable prevention of minor degrees of AMS would greatly enhance the experience of many travellers. Travel to high altitudes may also aggravate underlying illnesses, particularly cardiopulmonary diseases (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>). Second, the true role of the many approaches for preventing acute HAI is uncertain (<a href="./references#CD009761-bbs2-0127" title="AdamsJ . Ginkgo biloba and acetazolamide for acute mountain sickness: exclusion of high risk, low status groups perpetuates discrimination and inequalities. BMJ2004;329(7458):171. [MEDLINE: 15258082] ">Adams 2004</a>; <a href="./references#CD009761-bbs2-0134" title="BärtschP , BaileyDM , BergerMM , KnauthM , BaumgartnerRW . Acute mountain sickness: controversies and advances. High Altitude Medicine &amp; Biology2004;5(2):110‐2. [MEDLINE: 15265333] ">Bärtsch 2004</a>; <a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>; <a href="./references#CD009761-bbs2-0144" title="ElphickHL , ElphickDA . Ginkgo biloba and acetazolamide for acute mountain sickness: bias in participants may underestimate effectiveness of agents. BMJ2004;329(7458):172. [MEDLINE: 15258084] ">Elphick 2004</a>), meaning that their clinical effectiveness and safety must be assessed. Third, it is necessary to answer questions such as: Are all of these interventions equally useful regardless of the type of HAI? and Is there a reason to believe that some forms are more appropriate for some persons at risk than others?. Four, an updated meta‐analysis on AMS prevention needs to be produced (<a href="./references#CD009761-bbs2-0142" title="DumontL , MardirosoffC , TramèrMR . Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ2000;321(7256):267‐72. [MEDLINE: 10915127] ">Dumont 2000</a>). </p> <p>A systematic review, including a rigorous assessment of the risks of bias, of the most up‐to‐date evidence, will help clinicians make informed decisions about the use of non‐pharmacological and pharmacological interventions for preventing acute HAI. The protocol for this review included all agents to prevent high altitude illness (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), but we have decided to split the review into a series of three publications about the prevention of this condition (Part 1: Commonly‐used drugs. Part 2: Less commonly‐used drugs. Part 3: Miscellaneous and non‐pharmacological interventions). This review includes six groups of the most highly recommended agents to prevent acute HAI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009761-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009761-sec-0039"></div> <p>To assess the clinical effectiveness and adverse events of commonly‐used interventions for preventing acute HAI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009761-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009761-sec-0040"></div> <section id="CD009761-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009761-sec-0042"> <h4 class="title">Types of studies</h4> <p>We include randomized controlled trials (RCTs) irrespective of publication status (trials may be unpublished or published as articles, abstracts, or letters), language (no language limitation) or country. We applied no restrictions by length of follow‐up. We also included cross‐over trials (See <a href="#CD009761-sec-0272">Differences between protocol and review</a> and section). </p> <p>We excluded quasi‐randomized studies and prospective observational studies for evaluating clinical effectiveness. </p> </section> <section id="CD009761-sec-0043"> <h4 class="title">Types of participants</h4> <p>We include trials involving participants who are at risk of developing high altitude illness (AMS or HACE, HAPE). We include participants with and without a history of high altitude illness. We applied no age or gender restrictions. </p> </section> <section id="CD009761-sec-0044"> <h4 class="title">Types of interventions</h4> <p>The published protocol for this review included all agents to prevent high altitude illness (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>). However we decided to split the topic into a series of three publications about the prevention of this condition (See <a href="#CD009761-sec-0272">Differences between protocol and review</a> section). This is the first of the three and includes the following six groups of the most widely recommended agents to prevent acute HAI: </p> <p> <ol id="CD009761-list-0003"> <li> <p>Carbonic anhydrase inhibitors: Including acetazolamide and methazolamide.</p> </li> <li> <p>Steroids: Including budenoside, prednisolone and dexamethasone.</p> </li> <li> <p>Bronchodilator drugs: Including salmeterol, theophyline and montelukast.</p> </li> <li> <p>Selective inhibitor of phosphodiesterase type 5 (PDE5): Including taladafil and sildenafil.</p> </li> <li> <p>Calcium channel modulators: Including nifedipine and flunarizine.</p> </li> <li> <p>Non‐steroidal anti‐inflammatory drugs (NSAIDs) and other analgesics: Including aspirin, carbasalate and ibuprofen. </p> </li> </ol> </p> <p>We include trials where the relevant medication was administered before beginning the ascent. We exclude trials using these drugs during or after the ascent. </p> </section> <section id="CD009761-sec-0045"> <h4 class="title">Types of outcome measures</h4> <p>We modified the following outcome measures from the published protocol (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>). This is a departure from the protocol and it is explained in the <a href="#CD009761-sec-0272">Differences between protocol and review</a> section. </p> <section id="CD009761-sec-0046"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009761-list-0004"> <li> <p>Incidence of acute mountain sickness (AMS ‐ as defined by each study) at any time.</p> </li> </ol> </p> </section> <section id="CD009761-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009761-list-0005"> <li> <p>Incidence of high altitude pulmonary oedema (HAPE ‐ as defined by each study) at any time. </p> </li> <li> <p>Incidence of high altitude cerebral oedema (HACE ‐ as defined by each study), at any time. </p> </li> <li> <p>Incidence of adverse events in general, including paraesthesia, at any time.</p> </li> <li> <p>Differences in HAI/AMS scores at high altitude. We analysed the differences between groups by any measure of AMS severity and between 0 and 48 hours at high altitude. </p> </li> </ol> </p> </section> </section> </section> <section id="CD009761-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the same search methods for the identification of studies, which are common to the three reviews included in this series. </p> <section id="CD009761-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, January 2017); MEDLINE (OVID, 1966 to January 2017); Embase (OVID, 1980 to January 2017); LILACS (1982 to January 2017). We used the specific search terms listed below in combination with the Cochrane highly sensitive search strategy for identifying randomized controlled trials (RCTs) in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>). <a href="./appendices#CD009761-sec-0255">Appendix 4</a> to <a href="./appendices#CD009761-sec-0258">Appendix 7</a> show the search strategies used in this set of reviews. We undertook the most recent search in January 2017. </p> </section> <section id="CD009761-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We also searched trials registries through the World Health Organization International Clinical Trials Registry Platform Search Portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">ICTRP</a>) (see <a href="./appendices#CD009761-sec-0259">Appendix 8</a>). We looked through the reference lists of the retrieved publications and review articles. We undertook the most recent search in January 2017. </p> </section> </section> <section id="CD009761-sec-0051"> <h3 class="title" id="CD009761-sec-0051">Data collection and analysis</h3> <p>Data collection and analysis methods were common to the three reviews included in this series. </p> <section id="CD009761-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed each reference identified by the search against the inclusion criteria. We resolved any disagreements by discussion, and by consultation with a third review author as an arbiter if we could not reach agreement. We retrieved in full those references which appeared to meet the inclusion criteria for further independent assessment by the same three review authors. </p> </section> <section id="CD009761-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>We used a predefined form to extract the following data: eligibility criteria, demographics (age, gender, country), rate of ascent (metres/hour), final altitude reached (metres), AMS scale, design study, history of HAI, type of HAI, proposed intervention, and main outcomes, among others. See <a href="./appendices#CD009761-sec-0260">Appendix 9</a> for details of the data extraction form. For eligible studies, two review authors extracted the data using the selected form. We resolved discrepancies through discussion or, if required, we involved a third review author. We entered data into Review Manager 5 software and checked them for accuracy. </p> </section> <section id="CD009761-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors independently assessed risks of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreement by discussion. We judged the methodological quality of each study using Cochrane’s process for assessing risk of bias, a two‐part tool that addresses the six specific domains: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective reporting; and other potential biases (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>). The first part describes the risk of bias; the second part provides criteria for making judgements about the risk of bias from each of the six domains (<a href="./appendices#CD009761-sec-0260">Appendix 9</a>). Based on this process we implemented a 'Risk of bias' worksheet to be filled out for each study. Two review authors independently assessed the risks of bias, resolving any disagreement through consultation with an additional review author. We display the results by creating a 'Risk of bias' graph and a 'Risk of bias' summary figure using <a href="./references#CD009761-bbs2-0186" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a> software, if appropriate. We present the risks of bias in the <a href="./full#CD009761-sec-0064">Results</a> section. We also provided summary assessments of the risks of bias for each outcome within and across studies. </p> </section> <section id="CD009761-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (such as incidence of AMS or HAPE), we show results as summary risk ratios (RRs) with 95% confidence intervals (CIs). For continuous outcomes (such as differences in AMS scores), we present the results as summary mean differences (MDs) or standardized mean differences (SMDs) as appropriate, with a 95% CI. Because we identified a considerable number of cross‐over trials, we have included these studies separately and analysed this information using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions‐ Chapter 16.4</i> (<a href="./references#CD009761-bbs2-0143" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [PUBMED: 11914310] ">Elbourne 2002</a>; <a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD009761-bbs2-0197" title="StedmanMR , CurtinF , ElbourneDR , KesselheimAS , BrookhartMA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2011;40(6):1732‐4. [PUBMED: 20026595] ">Stedman 2011</a>), specifically related to estimation of the Mantel‐Haenzel odds ratio (OR) for paired outcomes. </p> </section> <section id="CD009761-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>The published protocol did not include consideration of any unit of analysis issues. However, our searches identified 12 cross‐over studies and we included them in the analyses, but separately from the parallel studies. In brief, we used the methods recommended by Elbourne (<a href="./references#CD009761-bbs2-0143" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [PUBMED: 11914310] ">Elbourne 2002</a>; <a href="./references#CD009761-bbs2-0197" title="StedmanMR , CurtinF , ElbourneDR , KesselheimAS , BrookhartMA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2011;40(6):1732‐4. [PUBMED: 20026595] ">Stedman 2011</a>). This is a departure from the protocol (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>) and is explained in the <a href="#CD009761-sec-0272">Differences between protocol and review</a> section. </p> </section> <section id="CD009761-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat (ITT) basis (i.e. we attempted to include all randomized participants in the denominator of the assessed groups in the analyses). Due to the fact that we included studies with missing information (especially standard deviations) or data not suitable for planned analyses, we followed the methods recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions‐ Chapter 16.1.3.</i> (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>). In brief, we transformed median values and their interquartile ranges or range extracted from included studies to means and standard deviations according to Wan and colleagues (<a href="./references#CD009761-bbs2-0160" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [PUBMED: 15840177] ">Hozo 2005</a>; <a href="./references#CD009761-bbs2-0204" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135. [PUBMED: 25524443] ">Wan 2014</a>). This is a departure from the protocol (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>) and it is explained in the <a href="#CD009761-sec-0272">Differences between protocol and review</a> section. </p> </section> <section id="CD009761-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure statistical heterogeneity among the trials in each analysis. When we identified substantial heterogeneity, we explored it by prespecified subgroup analysis. The I<sup>2</sup> statistic describes the percentage of total variation across trials due to heterogeneity rather than sampling error (<a href="./references#CD009761-bbs2-0157" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). We considered a value for I<sup>2</sup> greater than 50% (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>) to be statistically significant. We assessed the clinical and methodological diversity of the included studies in a comparison for sufficient homogeneity before choosing to estimate summary effect sizes. </p> </section> <section id="CD009761-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed whether the review was subject to publication bias by using a funnel plot to graphically illustrate variability between trials. If we detected asymmetry, we planned to explore causes other than publication bias. We produced a funnel plot if we could include 10 or more RCTs in a comparison. </p> </section> <section id="CD009761-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We summarized the findings using the random‐effects model (<a href="./references#CD009761-bbs2-0141" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We carried out statistical analyses using Review Manager 5 (<a href="./references#CD009761-bbs2-0186" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a>). We interpreted differences as important where the 95% confidence interval did not cross the value of no difference between groups. We also applied trial sequential analysis, as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD009761-bbs2-0132" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD009761-bbs2-0205" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). To minimize random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD009761-bbs2-0205" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). The required information size calculation also accounted for the heterogeneity or diversity present in the meta‐analysis (<a href="./references#CD009761-bbs2-0205" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In our meta‐analysis, we based the diversity‐adjusted required information size on the event proportion in the control group; assumption of a plausible risk ratio reduction (RRR) of 20% on the RR reduction observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta‐analysis. We added the trials according to the year of publication, and if more than one trial had been published in a year, we added trials alphabetically according to the last name of the first trial author. On the basis of the required information size, we constructed trial sequential monitoring boundaries (<a href="./references#CD009761-bbs2-0167" title="LanKKG , DemetsD . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. ">Lan 1983</a>; <a href="./references#CD009761-bbs2-0202" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD009761-bbs2-0205" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size; if the trial sequential monitoring boundary is crossed before the required information size is reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. On the other hand, if the boundary is not crossed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. This can be determined by assessing if the cumulative Z‐curve crosses the trial sequential boundaries. Furthermore, trial sequential analysis can test the futility before the required information size has been reached, i.e. trial sequential analysis provides an area of futility. If futility boundaries are crossed, then further trials may be unnecessary (<a href="./references#CD009761-bbs2-0138" title="Copenhagen Trial Unit. Trial Sequential Analysis Version. Copenhagen: Copenhagen Trial Unit, 2011. ">CTU 2011</a>). We conducted TSA using software from the Copenhagen Trial Unit (<a href="./references#CD009761-bbs2-0138" title="Copenhagen Trial Unit. Trial Sequential Analysis Version. Copenhagen: Copenhagen Trial Unit, 2011. ">CTU 2011</a>). This is a departure from the published protocol (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>). See the details in the <a href="#CD009761-sec-0272">Differences between protocol and review</a> section. </p> </section> <section id="CD009761-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated heterogeneity by an informed clinical evaluation of each outcome, combining data only when clinically appropriate. We also investigated statistical heterogeneity using the I<sup>2</sup> statistic, as described above. For the primary outcomes, we considered subgroup analysis for the following factors, as appropriate: </p> <p> <ol id="CD009761-list-0006"> <li> <p>Extreme altitude exposure versus high or very high exposure (high: 1500 to 3500 metres; very high: 3500 to 5500 metres ; and extreme: above 5500 metres ) (<a href="./references#CD009761-bbs2-0184" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [MEDLINE: 20808661] ">Paralikar 2010</a>). </p> </li> <li> <p>Presence or absence of people at high risk of HAI.</p> </li> <li> <p>The presence or absence of significant pre‐existing disease: cardiovascular diseases, chronic obstructive pulmonary disease (COPD), diabetes mellitus. </p> </li> </ol> </p> </section> <section id="CD009761-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis comparing the general results versus RCTs of high methodological quality (studies classified as having a 'low risk of bias' (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>)). We chose only three core domains: generation of allocation sequence, incomplete outcome data, and selective reporting bias. </p> <section id="CD009761-sec-0063"> <h5 class="title">Summary of findings tables</h5> <p>We used the GRADE system (<a href="./references#CD009761-bbs2-0145" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence"and why is it important to clinicians. BMJ2008;336(7651):995‐8. [MEDLINE: 18456631] '>Guyatt 2008</a>) to assess the quality of the body of evidence associated with primary outcomes (incidence of AMS, HAPE, HACE and adverse events), and we constructed three 'Summary of findings' tables using the GRADE profiler software for the three major comparisons in this review (acetazolamide versus placebo, budenoside versus placebo and dexamethasone versus placebo). The outcomes covered in these tables are the incidence of AMS, the incidence of HAPE, the incidence of HACE and adverse events (<a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the quality of a body of evidence considers within‐study risk of bias, directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias (<a href="./references#CD009761-bbs2-0130" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [PUBMED: 21208779] ">Balshem 2011</a>; <a href="./references#CD009761-bbs2-0146" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>; <a href="./references#CD009761-bbs2-0147" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011b</a>; <a href="./references#CD009761-bbs2-0148" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011c</a>; <a href="./references#CD009761-bbs2-0149" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence—indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011d</a>; <a href="./references#CD009761-bbs2-0150" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011e</a>; <a href="./references#CD009761-bbs2-0151" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011f</a>; <a href="./references#CD009761-bbs2-0152" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011g</a>; <a href="./references#CD009761-bbs2-0153" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011h</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009761-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009761-sec-0064"></div> <section id="CD009761-sec-0065"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009761-sec-0274" title="">Characteristics of included studies</a> and <a href="./references#CD009761-sec-0275" title="">Characteristics of excluded studies</a>. </p> <section id="CD009761-sec-0066"> <h4 class="title">Results of the search</h4> <p>We carried out the latest search strategies in January 2017 and identified 1280 references. After reviewing the references by title and abstract, we selected 173 of the citations to review as full texts (see <a href="#CD009761-fig-0001">Figure 1</a>). After reading the articles, we included 64 studies and 4547 participants (distributed across 78 references), excluded 38 studies (distributed in 40 references), classified 12 as ongoing studies, and 12 as studies awaiting assessment (most of them due to full text not yet available). We also identified 31 additional studies focusing on other interventions not covered by this review. We will incorporate these in subsequent reviews in this series. </p> <div class="figure" id="CD009761-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009761-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009761-sec-0067"> <h4 class="title">Included studies</h4> <p>Twelve of 64 included studies are cross‐over trials (18.7%) that we analysed separately (<a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>). Fifty‐four trials were developed at high altitude (84%), and the remaining 11 were performed in hypobaric chambers (17.1%; <a href="#CD009761-tbl-0004">Table 1</a>; <a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a>; <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>). </p> <div class="table" id="CD009761-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High mountain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Men (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Increased risk of AMS, HAPE or HACE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Administration timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trekking</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Final altitude (mts)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference between the endpoint and the baseline altitude (mts)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of ascent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definicion de AMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conflict of interest</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ecuador</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous episodes of HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4937</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score= headache + 1 symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>max 4 dias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐96 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ=AMS‐C SCORE&gt;0,70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% subjects with previous AMS mild or moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5334</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= 3 cerebral symptoms, one with intensity ≥2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of the subjects had previously visited high altitudes and had experienced mild to moderate AMS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5334</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= 3 cerebral symptoms, one with intensity ≥2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4846</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3480</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache scoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of AMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3800</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than a day by car up to 3480, and 2.8 to 3 hours climbing from there to 3800m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3480</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache scoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3630</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3700</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3800</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4392</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3459</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ‐C score &gt;0,5 or Lake Louise AMS score&gt;3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5895</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4243</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire clinical&gt;2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4400</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS Score&gt;2 or Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4930</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61,00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86,00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>susceptibility to AMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Score clinical proposed at the International Hypoxia symposium+ Do you feel ill?=Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4578</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ score &gt; = 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5896</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of of headache and at least one of the symptoms of nausea or vomiting, fatigue, dizziness, or difficulty sleeping, and a total score of at least 3, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4394</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAQ = Headache moderate or more and/or nausea moderate or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4394</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAQ = Headache moderate or more and/or nausea moderate or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3810</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3900</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kirguistán</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS score clinical= 3 or more symptoms with a grade 2 or greater</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3696</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,5 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS score clinical≥3 or 1 symptom=3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a> Def1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 to 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;28 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 to 74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>susceptible to HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 hours‐4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score= headache + 1 symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4875</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 to 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ AMS‐C Score≥0,7 + Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3561</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous severe AMS= 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4790</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4680</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4050</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3900</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LLS includes 5 self‐reporting symptoms:headache, gastrointestinal symptoms, fatigue/weakness, dizziness/lightheadedness and difficulty in sleeping. Each symptom is scores 0‐3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> </div> <section id="CD009761-sec-0068"> <h5 class="title">Participants</h5> <p>The participants' ages ranged between 16 and 65 years. Nineteen of the studies included only men (29.6%; <a href="#CD009761-tbl-0004">Table 1</a>. <a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>; <a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a>; <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>). </p> <p>Eleven out of 64 studies included people at high risk of AMS, HAPE or HACE, due to a history of these conditions or comorbidities such as asthma (17.1%; <a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>). </p> </section> <section id="CD009761-sec-0069"> <h5 class="title">Setting</h5> <p>Nineteen of the studies were undertaken in the USA (29.6%);17 were carried out in India (26.1%); and six out of 65 studies were carried out in South America (9.2%; <a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>; <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>). The remaining studies were carried out in other countries (<a href="#CD009761-tbl-0004">Table 1</a>)). </p> </section> <section id="CD009761-sec-0070"> <h5 class="title">Administration of intervention to prevent AMS</h5> <p>Twenty‐four out of 64 studies provided the intervention between three and five days prior to the ascent (37.5%; <a href="#CD009761-tbl-0004">Table 1</a>), and 22 between one and two days prior (34.3%; <a href="#CD009761-tbl-0004">Table 1</a>). The remaining studies provided the intervention in other time intervals. Four trials did not provide information about this issue (<a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). In 25% of the trials, the participants hiked to endpoint altitude (trekking), and 12 studies used a combination of means of transportation, including cars, trains, and cable‐cars (18.7%; <a href="#CD009761-tbl-0004">Table 1</a>). </p> </section> <section id="CD009761-sec-0071"> <h5 class="title">Altitude</h5> <p>Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level (59.3%; <a href="#CD009761-tbl-0004">Table 1</a>). The most frequent difference between the endpoint and the baseline altitude was 3001 to 4000 metres (35.9%; <a href="#CD009761-tbl-0004">Table 1</a>), followed by a difference of more than 4000 metres (28.1%). The most frequent durations for ascent were of less than five hours (14 studies, 21.8%; <a href="#CD009761-tbl-0004">Table 1</a>) and three days or more (14 studies, 21.8%; <a href="#CD009761-tbl-0004">Table 1</a>). Eighteen studies did not provide information about these issues (28.1%; <a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>; <a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>). </p> </section> <section id="CD009761-sec-0072"> <h5 class="title">Scale used to assess AMS</h5> <p>The most commonly‐used scale used was the Lake Louise Score (23 trials, 35.9%), and the criterion to define AMS onset was a score three or more points in eight trials (12.5%; <a href="#CD009761-tbl-0004">Table 1</a>. <a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). In 19 studies,the criteria used to define the onset of AMS were unclear (29.6%; <a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a>; <a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a>; <a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>). </p> </section> <section id="CD009761-sec-0073"> <h5 class="title">Funding</h5> <p>In 23 of the included studies, the source of funding was unclear (35.9%; <a href="#CD009761-tbl-0004">Table 1</a>), and only 19 of 64 studies declared their possible conflicts of interests (29.6%; <a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>). </p> </section> </section> <section id="CD009761-sec-0074"> <h4 class="title">Excluded studies</h4> <p>We excluded 38 studies (40 references) from the review. Twenty‐eight out of 38 were excluded for not focusing on HAI or AMS prevention (73.6%), but reported instead physiological or laboratory results related to altitude ascent. In eight studies, authors reported results for the treatment of HAI or AMS (21%). We excluded the remaining references for other reasons. Readers can find more information about this aspect in the <a href="./references#CD009761-sec-0275" title="">Characteristics of excluded studies</a>. </p> <section id="CD009761-sec-0075"> <h5 class="title">Studies awaiting classification</h5> <p>We classified 12 studies (<a href="./references#CD009761-bbs2-0103" title="DugasL , DubrayC , HerryJP , OlsenNV , Court‐PayenM , HansenJM , et al. Cardiovascular effects of a calcium channel blocker in hypoxia caused by altitude [Effets cardiovasculaires d'un bloqueur calcique en hypoxie d'altitude]. Presse Medicale1995;24(16):763‐8. [PUBMED: 7784415] ">Dugas 1995</a>; <a href="./references#CD009761-bbs2-0104" title="EllsworthAJ , LarsonEB , StricklandD . A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. American Journal of Medicine1987;83(6):1024‐30. [PUBMED: 3332564] ">Ellsworth 1987</a>; <a href="./references#CD009761-bbs2-0105" title="FurianM , LichtblauM , AeschbacherSS , BisangM , HartmannSE , PoulinM , et al. Altitude related adverse health effects in lowlanders with COPD travelling to 3,200 m. randomized trial of preventive dexamethasone treatment. Respiration2016;91(5):415. ">Furian 2016</a>; <a href="./references#CD009761-bbs2-0106" title="HeftiJP , StutzM , GeiserT , HeftiU , MerzT , HuberA . Effect of antioxidant supplements on AMS and endothelial function during a high altitude expedition: A prospective randomized double‐blind trial. High Altitude Medicine &amp; Biology2014;15(2):A262. ">Hefti 2014</a>; <a href="./references#CD009761-bbs2-0107" title="KasicJF , YaronM , NicholasRA , LickteigJA , RoachR . Treatment of acute mountain‐sickness ‐ hyperbaric versus oxygen‐therapy. Annals of Emergency Medicine1991;20(10):1109‐12. ">Kasic 1991</a>; <a href="./references#CD009761-bbs2-0108" title="LeeJH , ChoiPC . Comparison of methazolamide and acetazolamide for prevention of acute mountain sickness in adolescents. Journal of the Korean Society of Emergency Medicine2011;22(5):523‐30. ">Lee 2011</a>; <a href="./references#CD009761-bbs2-0109" title="PunM , NeupaneM , LohaniA , ThapaGB , YadavS , HolckPS , et al. Role of low‐dose acetazolamide (125 mg BID) in prevention of acute mountain sickness in pilgrims ascending rapidly: A prospective double‐blind placebocontrolled randomized trial. High Altitude Medicine &amp; Biology2014;15(2):A233. ">Pun 2014</a>; <a href="./references#CD009761-bbs2-0110" title="RoncinJP , SchwartzF , DarbignyP . EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviation, Space, and Environmental Medicine1996;67(5):445‐52. ">Roncin 1996</a>; <a href="./references#CD009761-bbs2-0111" title="SwensonER , MacdonaldA , VatheuerM , MaksC , TreadwellA , AllenR , et al. Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Aviation, Space, and Environmental Medicine1997;68:499‐503. ">Swenson 1997</a>; <a href="./references#CD009761-bbs2-0112" title="UtzG , SchlierfG , BarthP , LinhartP , WollenweberJ . Prevention of acute mountain sickness using acetazolamide [Prophylaxe der akuten hohenkrankheit mit acetazolamid]. Munchener Medizinische Wochenschrift1970;112(23):1122‐4. [PUBMED: 5467747] ">Utz 1970</a>; <a href="./references#CD009761-bbs2-0113" title="WangW , ZhangX , MaY . Low‐concentration nitrous oxide inhalation in the treatment of high‐altitude pulmonary edema. Chinese Journal of Tuberculosis and Respiratory Diseases1998;21(4):212‐4. ">Wang 1998</a>; <a href="./references#CD009761-bbs2-0114" title="XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: a double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;64(16 Suppl 1):C69. ">Xiangjun 2014</a>) as awaiting assessment. We were unable to obtain the full texts from the authors, the Anaesthesia, Critical and Emergency Care Cochrane Group (ACE) or the Iberoamerican Cochrane Centre. See <a href="./references#CD009761-sec-0276" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD009761-sec-0076"> <h5 class="title">Ongoing studies</h5> <p>We considered 12 additional studies to be ongoing (<a href="./references#CD009761-bbs2-0115" title="ChiCTR‐TRC‐13003319 . Oral zolpidem for improving sleep and then prevention of acute mountain sickness: a single centre, randomized, double‐blind, controlled, prospective trial. www.chictr.org.cn/hvshowproject.aspx?id=6053 (first received 28th June 2013). ">ChiCTR‐TRC‐13003319</a>; <a href="./references#CD009761-bbs2-0116" title="ChiCTR‐TRC‐13003590 . The Meaning of Intravenous Iron Supplementation In Acute Mountain Sickness: A Randomized, Double‐Blinded, Placebo‐Controlled Trail. http://www.chictr.org.cn/showproj.aspx?proj=5970 (first published 23 June 2013). ">ChiCTR‐TRC‐13003590</a>; <a href="./references#CD009761-bbs2-0117" title="NCT00886912 . Prevention of Acute Mountain Sickness (AMS) by Intermittent Hypoxic Training. http://clinicaltrials.gov/show/NCT00886912 Date of registration: April 21th 2009. ">NCT00886912</a>; <a href="./references#CD009761-bbs2-0118" title="NCT01606527 . Prospective, Double‐blind, Randomized, Placebo‐controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness. http://clinicaltrials.gov/show/NCT01606527 April 13th 2012. ">NCT01606527</a>; <a href="./references#CD009761-bbs2-0119" title="NCT01682551 . Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness. http://clinicaltrials.gov/show/NCT01682551 September 5th 2012. ">NCT01682551</a>; <a href="./references#CD009761-bbs2-0120" title="NCT01794078 . A Randomized, 4‐Sequence, Double‐Blind Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude. https://clinicaltrials.gov/show/NCT01794078 February 10th 2013. ">NCT01794078</a>; <a href="./references#CD009761-bbs2-0121" title="NCT01993667 . Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing. https://clinicaltrials.gov/show/NCT01993667 November 12th 2013. ">NCT01993667</a>; <a href="./references#CD009761-bbs2-0122" title="NCT02244437 . Ibuprofen vs Acetaminophen in the Prevention of Acute Mountain Sickness: A Double Blind, Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT02244437 September 14th 2014. ">NCT02244437</a>; <a href="./references#CD009761-bbs2-0123" title="NCT02450968 . Dexamethasone for Prophylaxis of Acute Mountain Sickness in Patients With Chronic Obstructive Pulmonary Disease Travelling to Altitude. https://clinicaltrials.gov/show/NCT02450968 May 18th 2015. ">NCT02450968</a>; <a href="./references#CD009761-bbs2-0124" title="NCT02604173 . A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments. https://clinicaltrials.gov/show/NCT02604173 November 6th 2015. ">NCT02604173</a>; <a href="./references#CD009761-bbs2-0125" title="NCT02811016 . Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m. https://clinicaltrials.gov/show/NCT02811016 June 14th 2016. ">NCT02811016</a>; <a href="./references#CD009761-bbs2-0126" title="NCT02941510 . Inhaled Budesonide for Altitude Illness Prevention. https://clinicaltrials.gov/show/NCT02941510 October 19th 2016. ">NCT02941510</a>), given that we were only able to find them on trial registers, but we considered that they could be published shortly. See <a href="./references#CD009761-sec-0277" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD009761-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risks of bias for the studies across six domains. We provide a summary of our assessment of the methodological quality of included studies in <a href="#CD009761-fig-0002">Figure 2</a> and <a href="#CD009761-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009761-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009761-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009761-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009761-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009761-sec-0078"> <h4 class="title">Allocation</h4> <p>The authors reported a valid method of randomization in 19 studies, (<a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>; <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>), whereas this information was not clearly reported in the remaining studies (70.3%). Similarly, 14 studies undertook and reported random allocation concealment (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>), and the information was absent from the remaining included studies (78.1%). </p> </section> <section id="CD009761-sec-0079"> <h4 class="title">Blinding</h4> <p>Twenty‐two studies reported blinding of participants and personnel (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>; <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>). In two studies, we classified this domain as high risk (<a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a>; <a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>). </p> <p>We considered the risk of detection bias to be low in 12 studies (<a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>), and unclear in the remaining studies (81.2%). In eight studies, we rated the risk of bias as low for both performance and detection bias (<a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>). </p> </section> <section id="CD009761-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>Significant numbers of participants were lost or excluded from the final analysis of eight studies (<a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>). Nine further studies presented unclear data (<a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>). In the studies with minimal attrition bias, we often found that the data analyses were undertaken on a per protocol basis, and we took this into account for data collection, including all the randomized participants in the denominators of the assessed groups. </p> </section> <section id="CD009761-sec-0081"> <h4 class="title">Selective reporting</h4> <p>Reporting adverse events associated with the different types of interventions is fundamental to a complete assessment of their usefulness in clinical practice. We found that the majority of the studies did not report on adverse events associated with the classes of drugs commonly‐used for prevention of AMS (such as paraesthesia) (73.4%; <a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a>; <a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>; <a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>; <a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>; <a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a>; <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>; <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a>; <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). </p> <p>The remaining studies reported at least one adverse event related to the assessed intervention. </p> </section> <section id="CD009761-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>We found a possibility of industry bias in 29 studies, mainly related to the unclear role of the sponsors in the development of the study and the unknown effect of the first phase on cross‐over trials in final results (<a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>; <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>; <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>; <a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). We identified no other potential sources of risk in the remaining studies. </p> </section> </section> <section id="CD009761-sec-0083"> <h3 class="title" id="CD009761-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD009761-tbl-0001"><b>Summary of findings for the main comparison</b> Acetazolamide compared with placebo for preventing high altitude illness</a>; <a href="./full#CD009761-tbl-0002"><b>Summary of findings 2</b> Budesonide compared with placebo for preventing high altitude illness</a>; <a href="./full#CD009761-tbl-0003"><b>Summary of findings 3</b> Dexamethasone compared with placebo for preventing high altitude illness</a> </p> <p>See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD009761-sec-0084"> <h4 class="title">GROUP 1: Carbonic anhydrase inhibitors</h4> <section id="CD009761-sec-0085"> <h5 class="title">Comparison 1: carbonic anhydrase inhibitors: acetazolamide versus placebo</h5> <p>For this comparison, we included information from 28 parallel studies (2345 participants) (<a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a>; <a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). </p> <p>All trials were performed in high mountain areas. Many of the studies administered acetazolamide or placebo between three and five days prior to ascent (13 out of 28; 46.4%) with doses of 500 mg/day (13 out of 28 studies, 46.4%; <a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). For the assessment of AMS, the most widely‐used scale was the Lake Louise Score (12 out of 28 studies, 42.8%) with scores of three or more with headache as a definition of AMS (4 out of 28 trials, 14.2%; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>). Two studies involved people with a history of AMS, HAPE or HACE (<a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>). </p> <p>Most of the studies reached altitudes of between 3001 to 4000 metres (<a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). All but four studies included very high altitude exposure (i.e. 3500 to 5500 metres; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). </p> <p>Seven studies did not provide any information about any of the outcomes assessed in this review (<a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a>; <a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a>; <a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a>; <a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a>). Because <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> and <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a> evaluated two different groups that had been administered doses of acetazolamide, we included this information for the following analyses. Finally, in <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> two different definitions of HAI were provided and we chose information according to the second definition (Lake Louise AMS score of three or more with headache). </p> <p>In addition, we analysed information from five cross‐over trials (<a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>; <a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>) with a total of 54 participants. <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a> only reported medians for scores of AMS, precluding the inclusion of this information in the following analysis. </p> </section> <section id="CD009761-sec-0086"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Sixteen parallel studies provided information about this outcome (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a>; <a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>), registering a total of 391 events of acute mountain sickness (Incidence of AMS: 16.9%). The risk ratio (RR) for acute mountain sickness, comparing acetazolamide to placebo, was 0.47 (95% confidence interval (CI) 0.39 to 0.56; I<sup>2</sup> = 0%; 16 trials, 2301 participants; <a href="./references#CD009761-fig-0007" title="">Analysis 1.1</a>; <a href="#CD009761-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009761-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness." data-id="CD009761-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness. </p> </div> </div> </div> <p>We downgraded the quality of evidence from high to moderate, due to unclear risks of selection, detection, and performance bias in most of the included studies (See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>). In addition, when we considered the dosage of acetazolamide, we found a non‐statistically significant reduction in the risk of HAI in all groups (test for subgroup differences: Chi<sup>2</sup> = 4.55, df = 3; P = 0.21; I<sup>2</sup> = 34.0%. The RR for 250 to 255 mg is 0.60 (95% CI 0.39 to 0.94; I<sup>2</sup> = 14%; 4 trials, 855 participants). The RR for 500 mg is 0.48 (95% CI 0.38 to 0.61; I<sup>2</sup>= 0%; 8 trials, 1111 participants). The RR for 750 mg is 0.33 (95% CI 0.18 to 0.62; I<sup>2</sup> = 0%; 2 trials, 80 participants).The funnel plot did not show data asymmetry related to sample size (<a href="#CD009761-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009761-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness." data-id="CD009761-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness. </p> </div> </div> </div> <p>Regarding sensitivity analyses, only one study was at low risk of bias in the three core domains selected in the Methods section (<a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>). For our subgroup analyses, only one study includes an extreme altitude exposure (<a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>), and another includes people at high risk of HAI (<a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a>). In addition, two cross‐over studies (<a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a>) found four events of acute mountain sickness (total incidence of AMS = 16.6%). The odds ratios ranged from 1 to 4.3. The pooled odds ratio for AMS, comparing acetazolamide to placebo, was 2.26 (95% CI 0.54 to 9.40; I<sup>2</sup> = 56%), showing no effect of acetazolamide in the onset of HAI, but with considerable heterogeneity. </p> </section> <section id="CD009761-sec-0087"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>Seven parallel studies (1138 participants) evaluated the incidence of altitude pulmonary oedema (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>), but they did not find any events to report (<a href="./references#CD009761-fig-0008" title="">Analysis 1.2</a>). We downgraded the quality of evidence from high to moderate due to unclear risks of selection, detection, and performance bias (See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009761-sec-0088"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>Six parallel studies evaluated the incidence of altitude pulmonary oedema (<a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>; <a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>), but only one event was reported (incidence of HACE = 0.08%). The RR for HACE, comparing acetazolamide to placebo, was 0.32 (95% CI 0.01 to 7.48; 6 trials, 1126 participants; <a href="./references#CD009761-fig-0009" title="">Analysis 1.3</a>). We downgraded the quality of evidence from high to moderate due to unclear risks of selection, detection, and performance bias (See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009761-sec-0089"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>Five parallel studies provide information about paraesthesias (<a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a>; <a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>; <a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a>), for 279 events (incidence of paraesthesia = 35.3%). The RR for paraesthesia, comparing acetazolamide to placebo, was 5.53 (95% CI 2.81 to 10.88; I<sup>2</sup> = 60%; 789 participants; <a href="./references#CD009761-fig-0010" title="">Analysis 1.4</a>). This heterogeneity is reduced to 0% when the dosage of acetazolamide is taken into account (RR from 3.09 to 12.63 by dose; <a href="./references#CD009761-fig-0010" title="">Analysis 1.4</a>). We downgraded the quality of evidence from high to low due to unclear risks of selection, performance, and detection bias, as well as inconsistency (See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>One study (<a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>) evaluated the incidence of side effects in general, including paraesthesia and numbness. Sixty‐eight side effects were reported (incidence of side effects 17%). The risk of side effects, comparing acetazolamide to placebo, was 2.19 (95% CI 1.36 to 3.53) under intention‐to‐treat analysis. However, under per‐protocol analysis, the risk was 2.20 (95% CI 1.55 to 3.12). When the missing subjects were considered as cases of adverse events in both arms, the estimated risk was 1.15 (95% CI 1.08 to 1.23). We downgraded the quality of evidence from high to low due to these high levels of attrition bias (See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>). Another study (<a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>) evaluated the incidence of major events, including drug reactions and gastrointestinal bleeding. However, authors found no major events to report. Finally, in <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> the authors reported the incidence of numbness in fingers, with six events in 32 participants. </p> <p>One cross‐over study reported the incidence of tingling (<a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a>; 24 participants). The estimated OR for this adverse event, comparing acetazolamide to placebo, was 1.44 (95% CI 0.78 to 2.68). </p> </section> <section id="CD009761-sec-0090"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>Six parallel studies provide information about scores for AMS (<a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>; <a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a>; <a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a>; <a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a>). <a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> reported the scores for two doses of acetazolamide (250 mg and 500 mg) and compared them to a single common placebo group. To avoid double counting, we have presented the results as dosing subgroups only (<a href="./references#CD009761-fig-0011" title="">Analysis 1.5</a>). Pooling the data for all sets produced a heterogeneous effect estimate (I<sup>2</sup> = 80.4%). The standardized mean difference between acetazolamide and placebo was 0.19 for doses of 250 mg/day (95% CI 0.01 to 0.37; I<sup>2</sup> = 0%; 434 participants; <a href="./references#CD009761-fig-0011" title="">Analysis 1.5</a>). In contrast, the standardized mean difference between acetazolamide and placebo was ‐0.57 for doses of 500 mg/day, but with considerable heterogeneity (95% CI ‐1.20 to 0.07; I<sup>2</sup> = 72%; 92 participants; <a href="./references#CD009761-fig-0011" title="">Analysis 1.5</a>). </p> <p>In addition, two cross‐over studies reported differences in AMS scores, ranging from 1 to ‐2.7 (<a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>; 52 participants). The mean difference for these scores, comparing acetazolamide to placebo, was ‐1.25 (95% CI ‐4.79 to 2.29), but with considerable heterogeneity (I<sup>2</sup> = 78%). </p> </section> <section id="CD009761-sec-0091"> <h5 class="title">Trial sequential analysis for acetazolamide versus placebo</h5> <p>Trial sequential analysis of oral acetazolamide at any dose versus placebo for prevention of acute mountain sickness is based on the diversity‐adjusted required information size (DARIS) of 2396 participants. We calculated this DARIS based upon a proportion of participants with acute mountain sickness of 23.3% in the control group; a RRR of 20% in the experimental intervention group; an alpha of 5%; a beta of 20%; and a diversity of 0%. The cumulative Z‐curve (blue line) crossed the upper conventional alpha of 5% and the upper trial sequential alpha‐spending monitoring boundaries, showing that we have robust data for significant efficacy (<a href="#CD009761-fig-0006">Figure 6</a>). Likewise, trial sequential analysis of oral acetazolamide at 500 mg dose versus placebo for prevention of acute mountain sickness is based on a DARIS of 1759 participants. We calculated this DARIS based upon a proportion of participants with acute mountain sickness of 29.5% in the control group; a RRR of 20% in the experimental intervention group; an alpha of 5%; a beta of 20%; and a diversity of 0%. The cumulative Z‐curve (blue line) crossed the upper conventional alpha of 5% and the upper trial sequential alpha‐spending monitoring boundaries, showing that we have robust data for significant efficacy. Finally, TSA of oral acetazolamide at 250 mg dose versus placebo for prevention of acute mountain sickness is based on a DARIS of 1777 participants. We calculated this DARIS based upon a proportion of participants with acute mountain sickness of 13.1% in the control group; a RRR of 35% in the experimental intervention group; an alpha of 5%; a beta of 20%; and a diversity of 19%. The cumulative Z‐curve (blue line) twice crossed twice the upper conventional alpha of 5%, but it did not cross the upper trial sequential alpha‐spending monitoring boundaries, indicating that new randomized controlled trials are needed. Accordingly, after only 48.1% (855/1777) of the DARIS had been attained, we were able to reject an intervention effect of 35% or larger. </p> <div class="figure" id="CD009761-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial sequential analysis on prevention of acute mountain illness in 16 oral acetazolamide at any dose vs placebo trials" data-id="CD009761-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis on prevention of acute mountain illness in 16 oral acetazolamide at any dose vs placebo trials</b> </p> </div> </div> </div> </section> <section id="CD009761-sec-0092"> <h5 class="title">Comparison 2: carbonic anhydrase inhibitors: acetazolamide 250 mg versus acetazolamide 500 mg </h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a>) with 22 participants. This trial was carried out in the high mountain areas of Nepal, reaching a maximum altitude of 3630 metres. </p> </section> <section id="CD009761-sec-0093"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> did not identify any events of acute mountain sickness. </p> </section> <section id="CD009761-sec-0094"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0095"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0096"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0097"> <h5 class="title">Secondary outcome 4: differences in HAI or AMS scores</h5> <p><a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> provided information about differences in AMS scores. The mean difference for these scores, comparing 250 mg/day of acetazolamide versus 500 mg/day of acetazolamide, was 0.76 (95% CI ‐0.16 to 1.68). </p> </section> <section id="CD009761-sec-0098"> <h5 class="title">Comparison 3: carbonic anhydrase inhibitors: acetazolamide 750 mg versus acetazolamide 250mg </h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a>) with 156 participants. This study was carried out in high mountain areas of Nepal, reaching a maximum altitude of 4928 meters. </p> </section> <section id="CD009761-sec-0099"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>The authors of <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a> found 15 events of acute mountain sickness (incidence of AMS: 9.61%).The RR for acute mountain sickness, comparing 750 mg/day versus 250 mg/day of acetazolamide, was 0.60 (95% CI 0.22 to 1.61). </p> </section> <section id="CD009761-sec-0100"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0101"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0102"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>Authors of <a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a> reported information about paraesthesia, finding 117 events (incidence of paraesthesia: 75%). The RR for paraesthesias, comparing 750 mg/day versus 250 mg/day of acetazolamide, was 1.34 (95% CI 1.11 to 1.63). </p> </section> <section id="CD009761-sec-0103"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> </section> <section id="CD009761-sec-0104"> <h4 class="title">Group 2: Steroids</h4> <section id="CD009761-sec-0105"> <h5 class="title">Comparison 1: steroids: budenoside versus placebo</h5> <p>For this comparison, we analysed the information from two studies (<a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>; <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>) with 132 participants. Researchers administered 200 μg of inhaled budenoside twice daily in both studies. Both studies were carried out in China, reaching a maximum altitude of between 3700 to 3900 metres. </p> </section> <section id="CD009761-sec-0106"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Both studies provide information about the incidence of acute mountain sickness and found 45 events (incidence of AMS = 34%). The RR for AMS, comparing budenoside to placebo, was 0.37 (95% CI 0.23 to 0.61; I<sup>2</sup> = 0%; <a href="./references#CD009761-fig-0012" title="">Analysis 2.1</a>). We downgraded the quality of evidence from high to low, due to a high risk of performance bias, as well as imprecision issues (See <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD009761-sec-0107"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0108"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0109"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> assessed the incidence of side effects in general in all participants and did not find any events. We downgraded the quality of evidence from high to very low, due to a high risk of performance bias, as well as imprecision issues (See <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a>). Likewise, <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> evaluated the onset of persistent belching but did not find any affected participants. We downgraded the quality of evidence from high to low, due to imprecision issues (See <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD009761-sec-0110"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0111"> <h5 class="title">Comparison 2: steroids: dexamethasone versus placebo</h5> <p>For this comparison, we analysed the information from six studies in high mountain areas (<a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>), with a total of 205 participants. Two studies were carried out in the USA (<a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>), two in Nepal (<a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>), and one each in Pakistan (<a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>) and Bolivia (<a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>). <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> and <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a> included only men. All studies used scales other than the Lake Louise Score. <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> included 40% of participants with previous AMS, and the altitude reached was classified as extreme (more than 5000 metres). Two studies administered 16 mg of dexamethasone (<a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>), and most studies administered it during one to two days (<a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>). </p> <p><a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a> included the use of dexamethasone versus placebo at two different altitudes in two separate participant groups and the data for each has been presented separately (Montgomery 1989 (2,700m) and Montgomery 1989 (2,050m)).<a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> provided two definitions for AMS, but only one (modified Environmental Symptoms Questionnaire (ESQ) = 3 cerebral symptoms, one with intensity ≥ 2) provided information for further analyses. Data from <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>, <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a> and <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> about AMS scores were provided as medians and standard errors, which needed transformation for the corresponding analyses (See <a href="./appendices#CD009761-sec-0264">Appendix 10</a>). </p> <p>We also analysed information from five cross‐over studies (<a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>) with a total of 53 participants. The Rock 1989 study provided information for three different doses of dexamethasone, and we extracted and analysed the data separately (<a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>). </p> </section> <section id="CD009761-sec-0112"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Four parallel studies provided information about the incidence of acute mountain sickness (<a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a>; <a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a>), and found a total of 60 events (incidence of AMS = 34.09%). The RR for AMS, comparing dexamethasone versus placebo, was 0.60 (95% CI 0.36 to 1.00; I<sup>2</sup> = 39%; 176 participants; <a href="./references#CD009761-fig-0013" title="">Analysis 3.1</a>). We downgraded the quality of evidence from high to low, due to unclear risks of selection, performance, and detection bias, as well as imprecision issues (See <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a>). We found no numerical information about this outcome in the included cross‐over studies. In <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a> the authors reported six instances of AMS, but with no information on the number in each group. </p> <p>Regarding sensitivity analyses, none of the studies included in this comparison present low risk of bias in all the three domains previously selected. <a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> was the only study carried out at extreme altitude, and including a high‐risk population. Excluding this study from these analyses modified the pooled RR from 0.60 to 0.58, but increased the heterogeneity from 39% to 56%. </p> </section> <section id="CD009761-sec-0113"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0114"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0115"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> assessed the incidence of adverse events in general, but found no events to report. Likewise, <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> evaluated the onset of numbness in participants, but they too found no cases to report. We downgraded the quality of evidence from high to very low, due to unclear risks of selection, performance and detection bias, as well as imprecision issues (See <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a>). From the cross‐over studies, <a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a> found one event of dyspepsia for this comparison (total incidence of dyspepsia = 6.25%). The RR for dyspepsia, comparing dexamethasone to placebo was 1.36 (95% CI 0.40 to 4.60). </p> </section> <section id="CD009761-sec-0116"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>Three parallel studies provide information about AMS scores (<a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a>; <a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>). The standardized mean difference for these scores, comparing dexamethasone to placebo, was ‐0.46 (95% CI ‐1.21 to 0.29; I<sup>2</sup> = 38%; 50 participants; <a href="./references#CD009761-fig-0014" title="">Analysis 3.2</a>). We downgraded the quality of evidence from high to very low, due to unclear risks of selection, performance and detection bias, as well as imprecision issues (See <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a>). Five cross‐over studies reported information about this outcome (<a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a>; <a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a>; <a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a>; <a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a>; <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>). Mean differences ranged from ‐2.7 to 0.82 units. The MD for AMS scores, comparing dexamethasone to placebo, was ‐0.63 (95% CI ‐1.7 to 0.44), but with extreme heterogeneity (I<sup>2</sup> = 99%). </p> </section> <section id="CD009761-sec-0117"> <h5 class="title">Trial sequential analysis for dexamethasone versus placebo</h5> <p>Trial sequential analysis of dexamethazone versus placebo for prevention of acute mountain sickness is based on the diversity‐adjusted required information size (DARIS) of 517 participants. We calculated this DARIS based upon a proportion of participants with acute mountain illness of 44.9% in the control group; a RRR of 35% in the experimental intervention group; an alpha of 5%; a beta of 20%; and a diversity of 43%. After the fifth trial, the cumulative Z‐curve (blue line) crossed the upper conventional alpha of 5%, but it did not cross the upper trial sequential alpha‐spending monitoring boundaries. Accordingly, after only 34% (176/517) of the DARIS had been attained, we were able to reject an intervention effect of 35% or larger, indicating that new randomized controlled trials are needed. </p> </section> <section id="CD009761-sec-0118"> <h5 class="title">Comparison 3: steroids: prednisolone versus placebo</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a>) with 40 participants. However, this study did not provide information about any of the outcomes selected for this review. </p> </section> </section> <section id="CD009761-sec-0119"> <h4 class="title">Group 3: Brochodilators</h4> <section id="CD009761-sec-0120"> <h5 class="title">Comparison 1: bronchodilator drugs: salmeterol versus placebo</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a>) with 37 participants. Researchers administered 125 mg of inhaled salmeterol twice daily. This study was carried out in Nepal, reaching a maximum altitude of 4559 metres; all participants were susceptible to HAPE. </p> </section> <section id="CD009761-sec-0121"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0122"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a> provided information about the incidence of high‐altitude pulmonary oedema, with 20 events (incidence of HAPE = 54.05%). The RR for HAPE, comparing salmeterol to placebo, was 0.45 (95% CI 0.22 to 0.92; 37 participants). </p> </section> <section id="CD009761-sec-0123"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0124"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0125"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a> provided information about AMS scores. The mean difference for these scores, comparing salmeterol to placebo, was ‐5.70 (95% CI ‐8.50 to ‐2.90; 37 participants). </p> </section> <section id="CD009761-sec-0126"> <h5 class="title">Comparison 2: bronchodilators drugs: theophyline versus placebo</h5> <p>For this comparison, we identified two parallel studies with at least 20 participants (<a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a>; <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a>). The number of participants in <a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a> was unclear, and this precludes the use of this study in further analyses. In addition, we analysed information from two cross‐over studies (<a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a>; <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a>) with a total of 24 participants. However, in <a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a> the authors only provided information for AMS scores as medians, precluding the inclusion of this information in further analyses. </p> </section> <section id="CD009761-sec-0127"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Only <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a> provided information about the incidence of acute mountain sickness, with 12 events (incidence of AMS = 60%). The RR for AMS, comparing theophyline to placebo, was 0.71 (95% CI 0.34 to 1.50; 20 male participants). </p> </section> <section id="CD009761-sec-0128"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0129"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0130"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0131"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>Only <a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a> provided information about AMS scores for the parallel studies. The standardized mean difference for these scores, comparing theophyline to placebo, was ‐0.18 (95% CI ‐1.38 to 1.02; 20 participants). Of the cross‐over studies, only <a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a> reported information about scores for AMS.The mean difference between theophyline and placebo was ‐1.50 (95% CI ‐2.25 to ‐0.75). </p> </section> <section id="CD009761-sec-0132"> <h5 class="title">Comparison 3: bronchodilator drugs: montelukast versus placebo</h5> <p>For this comparison, we analysed information from two cross‐over studies (<a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a>; <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a>) with a total of 22 participants. <a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a> provided two definitions of AMS (Lake Louise Scale ≥ 3 and ESQ AMS‐C Score ≥ 0.7) and we selected the first one to include in analyses. </p> </section> <section id="CD009761-sec-0133"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a> found 14 events of acute mountain sickness (incidence of AMS = 58.3%). The odds ratio for AMS, comparing acetazolamide to placebo, was 1.47 (95% CI 0.61 to 3.55; 22 participants). </p> </section> <section id="CD009761-sec-0134"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0135"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0136"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0137"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>Both studies reported information about scores for AMS. Mean differences between montelukast and placebo ranged between 1.1 and ‐1.4. The mean difference between montelukast and placebo was ‐0.08 (95% CI ‐2.53 to 2.36; I<sup>2</sup> = 81%) but with considerable heterogeneity. </p> </section> </section> <section id="CD009761-sec-0138"> <h4 class="title">Group 4: Selective inhibitors of phosphodiesterase‐5</h4> <section id="CD009761-sec-0139"> <h5 class="title">Comparison 1: selective inhibitors of phosphodiesterase‐5: tadalafil versus placebo</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>) with 19 participants. The dosage of tadalafil used was 20 mg/day. This study was carried out in Kenya, reaching a maximum altitude of 4559 metres. All participants had a history of HAPE. </p> </section> <section id="CD009761-sec-0140"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> provided information about the incidence of acute mountain sickness, with 16 events (incidence of AMS = 84.2%). The RR for AMS, comparing tadalafil to placebo, was 0.90 (95% CI 0.61 to 1.32; 29 participants). </p> </section> <section id="CD009761-sec-0141"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> provided information about the incidence of altitude pulmonary oedema, with eight events (incidence of HAPE = 42.1%). The RR for HAPE, comparing tadalafil to placebo, was 0.13 (95% CI 0.02 to 0.85; 29 participants). </p> </section> <section id="CD009761-sec-0142"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0143"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0144"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0145"> <h5 class="title">Comparison 2: selective inhibitors of phosphodiesterase‐5: sildenafil citrate versus placebo </h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a>) with 62 participants. The dosage of sildenafil citrate used was 150 mg/day. This study was carried out in Chile, reaching a maximum altitude of 5200 metres. Data about AMS scores were provided as medians and interquartile ranges, and we transformed them for further analyses (See <a href="./appendices#CD009761-sec-0264">Appendix 10</a>). </p> </section> <section id="CD009761-sec-0146"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a> provided information about the incidence of acute mountain sickness, with 39 events (incidence of AMS = 62.9%). The RR for AMS, comparing sildenafil citrate to placebo, was 1.31 (95% CI 0.91 to 1.89; 62 participants). </p> </section> <section id="CD009761-sec-0147"> <h5 class="title">Secondary outcome 1 risk of altitude pulmonary oedema</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0148"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0149"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0150"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a> provided information about AMS scores. The standardized mean difference for these scores, comparing sildenafil to placebo, was ‐2.41 (95% CI ‐3.95 to ‐0.87; 62 participants). </p> </section> </section> <section id="CD009761-sec-0151"> <h4 class="title">Group 5: Calcium channel modulators</h4> <section id="CD009761-sec-0152"> <h5 class="title">Comparison 1: calcium channel modulators: nifedipine versus placebo</h5> <p>For this comparison, we analysed the information from two studies (<a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>) with a total of 48 participants. Both studies used 60 mg/day of nifedipine. <a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a> was carried out in Nepal, reaching a maximum altitude of 4559 metres, while <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a> was carried out in Italy and reached the same maximum altitude. All of the participants in <a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a> had a history of HAPE, and most of the participants in <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a> had susceptibility to AMS. </p> </section> <section id="CD009761-sec-0153"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a> provided information about the incidence of acute mountain sickness, with 17 events (incidence of AMS = 62.9%). The RR for AMS, comparing nifedipine to placebo, was 1.04 (95% CI 0.58 to 1.87; 27 participants). </p> </section> <section id="CD009761-sec-0154"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a> provided information about the incidence of high altitude pulmonary oedema, with eight events (incidence of HAPE = 38.09%). The RR for HAPE, comparing nifedipine to placebo, was 0.16 (95% CI 0.02 to 1.06; 21 participants). </p> </section> <section id="CD009761-sec-0155"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0156"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0157"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>Both included studies provided information about AMS scores (<a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a>; <a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a>). Mean differences ranged from ‐1.25 to 0.07. The standardized mean difference for these scores, comparing nifedipine to placebo, was ‐0.56, (95% CI ‐1.85 to 0.74; I<sup>2</sup> = 78%; 48 participants; <a href="./references#CD009761-fig-0015" title="">Analysis 4.1</a>), but with considerable heterogeneity. </p> </section> <section id="CD009761-sec-0158"> <h5 class="title">Comparison 2: calcium channel modulators: flunarizine versus placebo</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a>) with 20 participants. <a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a> used a hypobaric chamber to assess the effectiveness of 10 mg of flunarizine at 4559 metres. </p> </section> <section id="CD009761-sec-0159"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a> provided information about the incidence of acute mountain sickness and found 14 events (incidence of AMS = 70%). The RR for AMS, comparing flunarizine to placebo, was 1.00 (95% CI 0.56 to 1.78; 20 participants). </p> </section> <section id="CD009761-sec-0160"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0161"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0162"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0163"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0164"> <h5 class="title">Group 6: non‐steroidal anti‐inflammatory drugs (NSAIDs)</h5> </section> <section id="CD009761-sec-0165"> <h5 class="title">Comparison 1: non‐steroidal anti‐inflammatory drugs (NSAIDs) and other analgesics: aspirin versus placebo </h5> <p>For this comparison, we analysed the information from two studies (<a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>) with a total of 60 participants. Both studies focused on headache at altitude, using a headache score to evaluate its onset. Aspirin 320 mg was used as a prophylaxis, given from one to two hours beforehand; both studies reached a maximum altitude of 2880 metres. </p> </section> <section id="CD009761-sec-0166"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Both studies provided information about the incidence of acute mountain sickness (<a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a>; <a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a>), and found a total of 31 events (incidence of AMS = 51.6%). RRs ranged from 0.13 to 0.60. The RR for AMS, comparing aspirin to placebo, was 0.35 (95% CI 0.06 to 1.95; I<sup>2</sup> = 68%; 60 participants; <a href="./references#CD009761-fig-0016" title="">Analysis 5.1</a>), but with considerable heterogeneity. </p> </section> <section id="CD009761-sec-0167"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0168"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0169"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a> assessed the incidence of major adverse events in general, but did not find any events to report. </p> </section> <section id="CD009761-sec-0170"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0171"> <h5 class="title">Comparison 2: non‐steroidal anti‐inflammatory drugs (NSAIDs) and other analgesics: ibuprofen versus placebo </h5> <p>For this comparison, we analysed the information from three studies (<a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>), with a total of 598 participants. Only <a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> and <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a> provided a clear definition to determine the onset of AMS (Lake Louise AMS score ≥ 3 with headache). Ibuprofen dosage ranged from 600 to 1800 mg. <a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> and <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> were developed in Nepal, reaching a maximum altitude of 4928 metres, while <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a> was developed in the USA, reaching a maximum altitude of 3810 metres. None of these studies included high‐risk populations. </p> </section> <section id="CD009761-sec-0172"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>Three studies provided information about the incidence of acute mountain sickness (<a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a>; <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>; <a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a>), and found a total of 154 events (incidence of AMS = 25.7%). The RR for AMS, comparing ibuprofen to placebo, was 0.64 (95% CI 0.49 to 0.82; I<sup>2</sup> = 0%; 598 participants; <a href="./references#CD009761-fig-0017" title="">Analysis 6.1</a>). Regarding sensitivity analyses, none of the included studies in this comparison were at low risk of bias in the three previously selected domains. Likewise, all three studies were developed at very high altitude and none of them included a population at high risk of developing HAI/AMS. </p> </section> <section id="CD009761-sec-0173"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> evaluated the incidence of altitude pulmonary oedema, but did not find any events to report. </p> </section> <section id="CD009761-sec-0174"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p><a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> evaluated the incidence of altitude cerebral oedema, but did not find any events to report. </p> </section> <section id="CD009761-sec-0175"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> assessed the incidence of major adverse events in general, but did not find any events to report. The authors of <a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> reported one event of black stools in the ibuprofen group. </p> </section> <section id="CD009761-sec-0176"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0177"> <h5 class="title">Trial sequential analysis for ibuprofen versus placebo</h5> <p>Trial sequential analysis of oral ibuprofen at any dose versus placebo for prevention of acute mountain sickness is based on a DARIS of 1532 participants. We calculated this DARIS based on a proportion of participants with acute mountain sickness of 32.6% in the control group; a RRR of 20% in the experimental intervention group; an alpha of 5%; a beta of 20%; and a diversity of 0%. After the second trial, the cumulative Z‐curve (blue line) crossed the upper conventional alpha of 5%, but it did not cross the upper trial sequential alpha‐spending monitoring boundaries, which were reached rather than crossed by the third trial. After only 39% (598/1532) of the DARIS had been reached, we were able to reject an intervention effect of 20% or larger, indicating that new randomized controlled trials are needed. </p> </section> <section id="CD009761-sec-0178"> <h5 class="title">Comparison 3: non‐steroidal anti‐inflammatory drugs (NSAIDs) and other analgesics: carbasalate versus placebo </h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a>) with 31 participants. <a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a> defined AMS in three different ways (Lake Louise AMS score ≥ 3 with headache; Lake Louise AMS score with headache and self‐score + functional score ≥ 4; and Lake Louise AMS score with headache and self‐score + functional score + clinical score ≥ 4). We chose the first definition for the following analyses. </p> </section> <section id="CD009761-sec-0179"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a> provided information about the incidence of acute mountain sickness and found a total of 26 events (incidence of AMS = 83.8%). The RR for AMS, comparing carbasalate to placebo, was 0.91 (95% CI 0.67 to 1.25; 31 participants). </p> </section> <section id="CD009761-sec-0180"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0181"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0182"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0183"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> </section> <section id="CD009761-sec-0184"> <h4 class="title">Group 7: Other comparisons</h4> <section id="CD009761-sec-0185"> <h5 class="title">Comparison 1: other comparisons: acetazolamide versus dexamethasone</h5> <p>For this comparison, we included information from three studies (<a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>), with a total of 46 participants. In <a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a>, investigators administered 750 mg/day of acetazolamide. The study was carried out in the USA, reaching a maximum altitude of 4392 metres. <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> and <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> used 500 mg/day of acetazolamide. <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> was carried out in Nepal, reaching a maximum altitude of 4050 metres. We also included information from a cross‐over study (<a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>), which compared acetazolamide 750 mg/day to 12 mg dexamethasone using a hypobaric chamber. </p> </section> <section id="CD009761-sec-0186"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0187"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0188"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0189"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> reported information about numbness in the fingers, finding six events (Incidence of numbness: 37.5%). The RR for numbness, comparing acetazolamide to dexamethasone, was 16.25 (95% CI 1.07 to 247.19; 16 participants). </p> </section> <section id="CD009761-sec-0190"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> provided information about differences in AMS scores at high altitude. The standardized mean difference for AMS scores, comparing acetazolamide to dexamethasone, was 0.292 (95% CI 0.06 to 0.52; 12 participants). We also found information about this outcome in <a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a>. The standardized mean difference for AMS scores, comparing acetazolamide to dexamethasone, was 0.00 (95% CI ‐0.23 to 0.23; 40 participants). </p> </section> <section id="CD009761-sec-0191"> <h5 class="title">Comparison 2: other comparisons: acetazolamide plus dexamethasone versus acetazolamide</h5> <p>For this comparison, we analysed information from three studies (<a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a>; <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>), with a total of 40 participants. <a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a> used 500 mg of acetazolamide/day plus 8 mg of dexamethasone/day. Forty per cent of the participants in this study had a history of previous mild or moderate AMS. This study was carried out in Italy, reaching a maximum altitude of 5334 metres. <a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> and <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> used 500 mg of acetazolamide/day plus 8 mg and 16 mg of dexamethasone/day respectively; there were no groups at risk of AMS, HAPE or HACE. <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> was carried out in Nepal, reaching a maximum altitude of 4050 metres. </p> </section> <section id="CD009761-sec-0192"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a> found eight events of acute mountain sickness (incidence of AMS: 61.5%).The RR for acute mountain sickness, comparing acetazolamide plus dexamethasone to acetazolamide plus placebo, was 0.70 (95% CI 0.28 to 1.77; 13 participants). </p> </section> <section id="CD009761-sec-0193"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0194"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0195"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> reported information about numbness in the fingers, finding 11 events (incidence of numbness: 73.3%). The RR for numbness, comparing acetazolamide plus dexamethasone to acetazolamide, was 0.73 (95% CI 0.39 to 1.35; 15 participants). </p> </section> <section id="CD009761-sec-0196"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> provided information about differences in AMS scores at high altitude. The mean difference for AMS scores, comparing acetazolamide to dexamethasone was ‐11.47 (95% CI ‐17.63 to ‐5.31; 12 participants). </p> </section> <section id="CD009761-sec-0197"> <h5 class="title">Comparison 3: other comparisons: acetazolamide plus dexamethasone versus dexamethasone</h5> <p>For this comparison, we included information from two studies (<a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a>; <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a>), with a total of 29 participants. In <a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> 500 mg of acetazolamide/day plus 16 mg of dexamethasone/day were used. This study was carried out in Nepal, reaching a maximum altitude of 4050 metres. </p> </section> <section id="CD009761-sec-0198"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0199"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0200"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included studies.</p> </section> <section id="CD009761-sec-0201"> <h5 class="title">Secondary outcome 3: Incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> reported information about numbness in fingers, finding five events (Incidence of numbness: 29.4%). The RR for numbness, comparing acetazolamide plus dexamethasone to dexamethasone was 12.22 (95% CI 0.78 to 191.46; 17 participants). </p> </section> <section id="CD009761-sec-0202"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> provided information about differences in AMS scores at high altitude. The mean difference for AMS scores, comparing acetazolamide plus dexamethasone to dexamethasone was ‐9.17 (95% CI ‐15.62 to ‐2.72; 12 participants). </p> </section> <section id="CD009761-sec-0203"> <h5 class="title">Comparison 4: other comparisons: acetazolamide versus ibuprofen</h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a>) with 254 participants. <a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> administered 225 mg of acetazolamide/day or 600 mg of ibuprofen/day. </p> </section> <section id="CD009761-sec-0204"> <h5 class="title">Primary outcome 1: risk of acute mountain sickness</h5> <p><a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> found 32 events of acute mountain sickness (incidence of AMS: 12.59%). The RR for AMS, comparing acetazolamide to ibuprofen, was 1.33 (95% CI 0.69 to 2.55; 163 participants). </p> </section> <section id="CD009761-sec-0205"> <h5 class="title">Secondary outcome 1: risk of altitude pulmonary oedema.</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0206"> <h5 class="title">Secondary outcome 2: risk of high altitude cerebral oedema</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0207"> <h5 class="title">Secondary outcome 3: adverse events</h5> <p><a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> did not identify any major adverse events. </p> </section> <section id="CD009761-sec-0208"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0209"> <h5 class="title">Comparison 5: other comparisons: acetazolamide versus methazolamide</h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a>) with 20 participants. <a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a> used 500 mg of acetazolamide/day and 100/150 mg of methazolamide/day. This study was carried out in high mountain areas of Nepal, reaching a maximum altitude of 4790 metres. Some participants in this study had a previous history of severe AMS. </p> </section> <section id="CD009761-sec-0210"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0211"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0212"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0213"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0214"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a> reported information about AMS scores.The standardized mean difference between acetazolamide and methazolamide, was ‐3.00 (95% CI ‐21.07 to 15.07; 20 participants). </p> </section> <section id="CD009761-sec-0215"> <h5 class="title">Comparison 6:other comparisons: budenoside plus formoterol versus placebo</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>) with 40 participants in the relevant arms. This study was carried out in China, reaching a maximum altitude of 3700 metres. </p> </section> <section id="CD009761-sec-0216"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> provide information about the incidence of acute mountain sickness and found 24 events (incidence of AMS = 60%). The RR for AMS, comparing budenoside plus formoterol to placebo, was 0.71 (95% CI 0.42 to 1.21; 40 participants). </p> </section> <section id="CD009761-sec-0217"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0218"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0219"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> assessed the incidence of side effects but found no events. </p> </section> <section id="CD009761-sec-0220"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0221"> <h5 class="title">Comparison 7: other comparisons: budenoside versus dexamethasone</h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a>) with 92 participants. <a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> used 400 mg of budenoside/day and 4 mg of dexamethasone/day. This study was carried out in China, reaching a maximum altitude of 4050 metres. </p> </section> <section id="CD009761-sec-0222"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> found 22 events of acute mountain sickness for this comparison (incidence of AMS = 23.9%). The RR for AMS, comparing budenoside to dexamethasone, was 0.83 (95% CI 0.40 to 1.73; 92 participants). </p> </section> <section id="CD009761-sec-0223"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study</p> </section> <section id="CD009761-sec-0224"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0225"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> found four events of persistent belching for this comparison (incidence of persistent blenching = 4.34%). The RR for persistent blenching, comparing budenoside to dexamethasone, was 0.11 (95% CI 0.01 to 2.01; 92 participants). </p> </section> <section id="CD009761-sec-0226"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study</p> </section> <section id="CD009761-sec-0227"> <h5 class="title">Comparison 8: other comparisons: budenoside versus budenoside plus formoterol</h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a>) with 40 participants in the relevant arms. This study used 400 mg of budenoside/day and 9 mg of formoterol/day. It was carried out in China, reaching a maximum altitude of 3700 metres. </p> </section> <section id="CD009761-sec-0228"> <h5 class="title">Primary outcome 1: incidence of acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> found 15 events of acute mountain sickness for this comparison (total incidence of AMS = 37.5%). The RR for AMS, comparing budenoside to budenoside plus formoterol, was 0.50 (95% CI 0.21 to 1.20; 40 participants). </p> </section> <section id="CD009761-sec-0229"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0230"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0231"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> did not find any side effects for this comparison. </p> </section> <section id="CD009761-sec-0232"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0233"> <h5 class="title">Comparison 9: other comparisons: dexamethasone versus prednisolone</h5> <p>For this comparison, we analysed the information from one study (<a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a>) with 40 participants. However, this study did not provide information about any of outcomes selected for this review. </p> </section> <section id="CD009761-sec-0234"> <h5 class="title">Comparison 10: other comparisons: tadalafil versus dexamethasone</h5> <p>For this comparison, we analysed information from one study (<a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a>) with 20 participants. <a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> used 20 mg of tadalafil/day and 16 mg of dexamethasone/day. This study was carried out in Kenya, reaching a maximum altitude of 4559 metres. All participants had a history of HAPE. </p> </section> <section id="CD009761-sec-0235"> <h5 class="title">Primary outcome 1: incidence of Acute mountain sickness (AMS)</h5> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> found 11 events of acute mountain sickness for this comparison (incidence of AMS = 55%). The RR for AMS, comparing tadalafil to dexamethasone, was 2.67 (95% CI 0.98 to 7.22; 20 participants). </p> </section> <section id="CD009761-sec-0236"> <h5 class="title">Secondary outcome 1: incidence of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> found one event of altitude pulmonary oedema for this comparison (incidence of AMS = 5%). The RR for HAPE, comparing tadalafil to dexamethasone, was 3.0 (95% CI 0.14 to 65.9; 20 participants). </p> </section> <section id="CD009761-sec-0237"> <h5 class="title">Secondary outcome 2: incidence of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD009761-sec-0238"> <h5 class="title">Secondary outcome 3: incidence of adverse events</h5> <p>We found no information about this outcome in the included study</p> </section> <section id="CD009761-sec-0239"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009761-sec-0240" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009761-sec-0240"></div> <section id="CD009761-sec-0241"> <h3 class="title" id="CD009761-sec-0241">Summary of main results</h3> <p>Evidence from 65 studies showed important findings for interventions included in this review (commonly‐used pharmacological interventions). We report results for the three more important comparisons: </p> <p><b>Acetazolamide versus placebo (28 parallel studies; 2345 participants)</b> </p> <p>Our systematic review included data from 28 parallel clinical studies (n = 2345 participants) and five cross‐over studies (n= 54 participants) that assessed the effectiveness of acetazolamide compared with a placebo for the prevention of high altitude illness. The risk of AMS was reduced with acetazolamide (RR 0.47; 95% CI 0.39 to 0.56; I<sup>2</sup> = 0%; 16 trials; 2301 participants; moderate quality of evidence). No events of HAPE were reported and only one event of HACE (RR 0.32; 95% CI 0.01 to 7.48; 6 parallel trials; 1126 participants; moderate quality of evidence). Few studies reported side effects for this comparison, and they showed an increase in the risk of paraesthesia with the intake of acetazolamide (5 studies, 789 participants; RR from 3.09 to 12.63 by acetazolamide dosage). </p> <p><b>Budenoside versus placebo (2 parallel studies; 132 participants)</b> </p> <p>Data on budenoside showed a reduction in the incidence of AMS compared with placebo (2 studies, 132 participants; RR 0.37; 95% CI 0.23 to 0.61; I<sup>2</sup> = 0%; low quality of evidence). The included studies did not report any events of HAPE or HACE, and they did not find side effects (low quality of the evidence). </p> <p><b>Dexamethasone versus placebo (7 parallel studies; 205 participants)</b> </p> <p>For dexamethasone, data did not show benefits of dexamethasone at any dosage (four studies, 176 participants; RR 0.60; 95% CI 0.36 to 1.00; I<sup>2</sup> = 39%; low quality of evidence). The studies did not report any events of HAPE or HACE, and we rated the evidence about adverse events as of very low quality. </p> <p>We did not find any studies comparing methazolamide with a placebo. We also did not find evidence of benefits of theophyline, montelukast, selective inhibitors of phosphodiesterase‐5 (such as tadalafil and sildenafil), nifedipine, flunarizine, aspirin or carbasalate in reducing the incidence of AMS. Finally, we found little information on other comparisons between different agents included in this review (i.e. ibuprofen versus placebo, acetazolamide versus dexamethasone). Combinations of these drugs did not deliver any benefits. </p> </section> <section id="CD009761-sec-0242"> <h3 class="title" id="CD009761-sec-0242">Overall completeness and applicability of evidence</h3> <p>We carried out a thorough search and identified an important number of studies addressing effectiveness and safety in the most commonly‐used pharmacological interventions for the prevention of HAI or AMS. We included 65 studies in our review, with more than 2000 participants. Those studies addressed around 15 comparisons with placebos, and 11 comparisons between different drugs. The data included participants of different age groups and both genders, as well as different high‐altitude settings, different final altitudes reached, transportation, and prophylaxis times. Our systematic search for studies and our data extraction procedures should have minimized the likelihood of missing relevant studies. The funnel plot for acetazolamide versus placebo was highly symmetrical, suggesting that the chance of having missed relevant studies was minimal, with no evidence of publication bias. Despite all this, we found a lack of reports of the duration of prophylaxis, duration of ascent, criteria to diagnose AMS, HAPE or HACE, or statistical data (such as standard deviations) in several of the included studies. The sparsity of reports of adverse events was the most frequent limitation of the included studies, as well as the wide range of criteria and scales used to determine the onset of acute mountain sickness. The identification of only one study for several of the comparisons was a common factor limiting the scope and strength of this review. </p> <p>The trial sequence analyses performed with on acetazolamide for the prevention of AMS suggest we have robust data for significant efficacy, which can be applied with some confidence in the field. </p> </section> <section id="CD009761-sec-0243"> <h3 class="title" id="CD009761-sec-0243">Quality of the evidence</h3> <p>We conducted GRADE assessments on outcomes of meta‐analyses and single trials. We were unable to rate the evidence from either pooled or non‐pooled estimates as high, due to either or both of the following reasons: </p> <p> <ol id="CD009761-list-0007"> <li> <p>small sample sizes</p> </li> <li> <p>the risk of bias from multiple sources, including the lack of adequate randomization methods, lack of blinding, high attrition, unclear reporting of outcomes, and bias in the presentation of data, among others. </p> </li> </ol> </p> <p>We also downgraded the evidence because of uncertainty in clinically relevant outcomes, reflected in wide confidence intervals, i.e. imprecision. See <a href="./full#CD009761-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD009761-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD009761-tbl-0003">summary of findings Table 3</a> for detailed assessments and the rationale for ratings. </p> </section> <section id="CD009761-sec-0244"> <h3 class="title" id="CD009761-sec-0244">Potential biases in the review process</h3> <p>In all cases, we followed the methodology for systematic reviews outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009761-bbs2-0158" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. .Available from handbook.cochrane.org. ">Higgins 2011</a>). However, we had to made extensive modifications to the published protocol (<a href="./references#CD009761-bbs2-0212" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), due to the need to update the methods under the current methodological guidelines for Cochrane Reviews. Readers should be aware of the potential biases related to these modifications (detailed in <a href="#CD009761-sec-0272">Differences between protocol and review</a>), as well as the decision to split the review into three parts, considering the numerous interventions assessed for HAI prevention. </p> <p>In this review we undertook a comprehensive search to identify clinical trials addressing the issue of effectiveness and safety of commonly‐used classes of drugs for preventing acute HAI. Twelve studies did not provide enough information to classify them as included or excluded, because they were published only as conference proceedings, or because we did not have access to the full texts when we were completing this review. We have also considered 12 additional studies as ongoing because they are published only as protocols and we may be able to decide whether or not to include them once they have been published. A potential source of bias in the review process is that most of the studies (more than 75%), did not report adverse events associated with the classes of drugs commonly‐used for the prevention of AMS. This constitutes a lack of information about the safety profile of the drugs in question. Likewise, we did not expect to encounter any unit of analysis issues, as we did not expect to find cross‐over studies. However, we identified 12 cross‐over studies (20%). In order to avoid bias in the development of our review, we have analysed those studies separately. </p> </section> <section id="CD009761-sec-0245"> <h3 class="title" id="CD009761-sec-0245">Agreements and disagreements with other studies or reviews</h3> <p>There are several examples of published reviews evaluating different interventions to prevent high altitude illness. We found that our results are similar to other non‐Cochrane reviews (<a href="./references#CD009761-bbs2-0170" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD009761-bbs2-0165" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD009761-bbs2-0189" title="RitchieND , BaggottAV , Andrew ToddWT . Acetazolamide for the prevention of acute mountain sickness‐‐a systematic review and meta‐analysis. Journal of Travel Medicine2012;19(5):298‐307. [PUBMED: 22943270] ">Ritchie 2012</a>; <a href="./references#CD009761-bbs2-0196" title="SeupaulRA , WelchJL , MalkaST , EmmettTW . Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Annals of Emergency Medicine2012;59(4):307‐317.e1. [PUBMED: 22153998] ">Seupaul 2012</a>; <a href="./references#CD009761-bbs2-0210" title="ZafrenK . Prevention of high altitude illness. Travel Medicine and Infectious Disease2014;12(1):29‐39. [PUBMED: 24393671] ">Zafren 2014</a>), regarding HAI/AMS prevention (<a href="./references#CD009761-bbs2-0136" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (Relevé des maladies transmissibles au Canada)2007;33(ACS‐5):1‐20. [MEDLINE: 17520777] ">CATMAT 2007</a>; <a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>; <a href="./references#CD009761-bbs2-0174" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness &amp; Environmental Medicine2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] ">Luks 2014</a>). Most of these reviews recommend acetazolamide (at doses of 500 mg/day) as the first choice for the prevention of this condition. A systematic review developed by <a href="./references#CD009761-bbs2-0142" title="DumontL , MardirosoffC , TramèrMR . Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ2000;321(7256):267‐72. [MEDLINE: 10915127] ">Dumont 2000</a> concludes that doses of 750 mg/day are more effective than 500 mg/day; however, our findings showed that effectiveness is similar for these two options, but there is no clear information on whether the incidence of adverse events is greater, due to the lack of information in the studies for this outcome. </p> <p>In 2014, <a href="./references#CD009761-bbs2-0201" title="TangE , ChenY , LuoY . Dexamethasone for the prevention of acute mountain sickness: systematic review and meta‐analysis. International Journal of Cardiology2014;173(2):133‐8. [PUBMED: 24679688] ">Tang 2014</a> published evidence in favour of the use of oral dexamethasone for the prevention of AMS. The authors of this review reported that dexamethasone could reduce the incidence of AMS, with an odds ratio of 6.03 (95% CI 2.23 to 21.00), compared with placebo. While they only identified eight studies comparing dexamethasone to placebo, we found six parallel trials and five cross‐over studies. Our analysis did not produce definitive evidence about the effectiveness of dexamethasone, but we rated this evidence as being of low quality. In addition, our trial sequential analyses suggest that new randomized controlled trials are needed for this intervention. We note that current guidelines about AMS prevention include recommendations about the use of dexamethasone to prevent HAI/AMS, in 2 mg doses every six hours or 4 mg every 12 hours (<a href="./references#CD009761-bbs2-0173" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [MEDLINE: 20591379] ">Luks 2010</a>; <a href="./references#CD009761-bbs2-0174" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness &amp; Environmental Medicine2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] ">Luks 2014</a>). For the use of non‐steroidal anti‐inflammatory drugs (NSAIDs), our results are similar to those published by <a href="./references#CD009761-bbs2-0183" title="PanditA , KarmacharyaP , PathakR , GiriS , AryalMR . Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta‐analysis. Journal of Community Hospital Internal Medicine Perspectives2014;4(4):1‐7. [PUBMED: 25317267] ">Pandit 2014</a>, and support the use of ibuprofen as an alternative for acetazolamide, despite the fact that they provide analyses for all pooled NSAIDs (OR 0.43; 95% CI 0.27 to 0.69, I<sup>2</sup> = 0%). We did not find any reviews about other options such as tadalafil, sildenafil, nifedipine, flunarizine or theophylline, and these are not recommended in current clinical practice guidelines for the prevention of this condition. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009761-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009761-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009761-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009761-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness." data-id="CD009761-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness." data-id="CD009761-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, outcome: 1.1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis on prevention of acute mountain illness in 16 oral acetazolamide at any dose vs placebo trials" data-id="CD009761-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p><b>Trial sequential analysis on prevention of acute mountain illness in 16 oral acetazolamide at any dose vs placebo trials</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 1 Incidence of acute mountain sickness." data-id="CD009761-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 2 Incidence of high altitude pulmonary oedema." data-id="CD009761-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 2 Incidence of high altitude pulmonary oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 3 Incidence of high altitude cerebral oedema." data-id="CD009761-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 3 Incidence of high altitude cerebral oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 4 Incidence of adverse events: Paraesthesia." data-id="CD009761-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 4 Incidence of adverse events: Paraesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 5 Differences in HAI/AMS scores." data-id="CD009761-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Carbonic anhydrase inhibitors: acetazolamide versus placebo, Outcome 5 Differences in HAI/AMS scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroids: budesonide vs. placebo, Outcome 1 Incidence of acute mountain sickness." data-id="CD009761-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Steroids: budesonide vs. placebo, Outcome 1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Steroids: dexamethasone vs. placebo, Outcome 1 Incidence of acute mountain sickness." data-id="CD009761-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Steroids: dexamethasone vs. placebo, Outcome 1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Steroids: dexamethasone vs. placebo, Outcome 2 Differences in HAI/AMS scores." data-id="CD009761-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Steroids: dexamethasone vs. placebo, Outcome 2 Differences in HAI/AMS scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium modulators: nifedipine vs. placebo, Outcome 1 Differences in HAI/AMS scores." data-id="CD009761-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Calcium modulators: nifedipine vs. placebo, Outcome 1 Differences in HAI/AMS scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NSAIDs and other analgesic: aspirin vs. placebo, Outcome 1 Incidence of AMS." data-id="CD009761-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 NSAIDs and other analgesic: aspirin vs. placebo, Outcome 1 Incidence of AMS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009761-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/urn:x-wiley:14651858:media:CD009761:CD009761-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_t/tCD009761-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 NSAIDs and other analgesic: ibuprofen vs. placebo, Outcome 1 Incidence of acute mountain sickness." data-id="CD009761-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 NSAIDs and other analgesic: ibuprofen vs. placebo, Outcome 1 Incidence of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/media/CDSR/CD009761/image_n/nCD009761-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009761-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetazolamide compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acetazolamide compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> acetazolamide<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetazolamide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/> (94 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.39 to 0.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2301<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of high altitude pulmonary oedema (HAPE)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1138<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These trials reported no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of high altitude cerebral oedema (HACE)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> <br/> (0.01 to 7.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1126<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: Paresthesias‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>504 per 1000</b><br/> (256 to 992) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.53</b> (2.81 to 10.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>789<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: side effects‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>232 per 1000</b><br/> (144 to 374) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.19</b> <br/> (1.36 to 3.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to unclear selection, performance and detection bias in most of included studies. High risk of attrition bias in five studies.<br/> <sup>2</sup>Risk of bias downgraded (‐1) due to unclear selection, performance and detection bias. </p> <p><sup>3</sup> Risk of bias downgraded (‐2) due to unclear selection, performance and detection bias, as well as considerable heterogeneity (60%)<br/> <sup>4</sup>Risk of bias downgraded (‐2) due to high levels of attrition bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetazolamide compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009761-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Budesonide compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> budenoside<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/> (139 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.37</b> <br/> (0.23 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude pulmonary oedema (HAPE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude cerebral oedema (HACE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: Side effects‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This trial reported no events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to high risk of performance bias in one out of two studies included.<br/> <sup>2</sup>Imprecision downgraded (‐1) due to insufficient sample size to determine whether there are differences or not between these two groups.<br/> <sup>3</sup>Risk of bias downgraded (‐1) due to high risk of performance bias.<br/> <sup>4</sup>Imprecision downgraded (‐2) due to insufficient sample size to determine whether there are differences or not between these two groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009761-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dexamethasone compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dexamethasone compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people at risk of high altitude illness </p> <p><b>Setting:</b> High altitude; studies undertaken in India, South America and USA.<br/> <b>Intervention:</b> dexamethasone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dexamethasone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of acute mountain sickness (AMS)‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b><br/> (162 to 449) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.36 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude pulmonary oedema (HAPE)</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of high altitude cerebral oedema (HACE)</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported for selected trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: General‐</b> Follow‐ up: From arrival to 24 hours later </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This trial reported no events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias downgraded (‐1) due to unclear risk of selection, performance and detection bias in almost all studies included.<br/> <sup>2</sup>Imprecision downgraded (‐1) due to insufficient sample size to determine whether there are differences or not between these two groups.<br/> <sup>3</sup>Risk of bias downgraded (‐1) due to unclear risk of selection, performance and detection bias.<br/> <sup>4</sup>Imprecision downgraded (‐2) due to insufficient sample size to determine whether there are differences or not between these two groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dexamethasone compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009761-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High mountain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Men (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Increased risk of AMS, HAPE or HACE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Administration timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trekking</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Final altitude (mts)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference between the endpoint and the baseline altitude (mts)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of ascent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definicion de AMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conflict of interest</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0001" title="Anonymous . Acetazolamide in control of acute mountain sickness. Lancet1981;1(8213):180‐3. [PUBMED: 6109857] ">Anonymous 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ecuador</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0002" title="GertschJH , CorbettB , HolckPS , MulcahyA , WattsM , StillwagonNT , et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness and Environmental Medicine2012;23(4):307‐15. ">ASCENT 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0003" title="BanderetLE . Self‐rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation, Space, and Environmental Medicine1977;48(1):19‐22. [PUBMED: 831706] ">Banderet 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0004" title="BartschP , MaggioriniM , RitterM , NotiC , VockP , OelzO . Prevention of high‐altitude pulmonary edema by nifedipine. New England Journal of Medicine1991;325(18):1284‐9. [PUBMED: 1922223] OelzO , MaggioriniM , RitterM , NotiC , WaberU , VockP , et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine1992;13(1):S65‐8. [PUBMED: 1483797] ">Bartsch 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous episodes of HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0005" title="BasnyatB , GertschJH , JohnsonEW , Castro‐MarinF , InoueY , YehC . Efficacy of low‐dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2003;4(1):45‐52. [PUBMED: 12713711] ">Basnyat 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4937</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score= headache + 1 symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0006" title="BasnyatB , HargroveJ , HolckPS , SrivastavS , AlekhK , GhimireLV , et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Altitude Medicine &amp; Biology2008;9(3):209‐16. [PUBMED: 18800957] ">Basnyat 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>max 4 dias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐96 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0007" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Glucocorticoids as prophylaxis against acute mountain sickness. Clinical Endocrinology2002;57(6):761‐7. [PUBMED: 12460326] ">Basu 2002a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0008" title="BasuM , SawhneyRC , KumarS , PalK , PrasadR , SelvamurthyW . Hypothalamic‐pituitary‐adrenal axis following glucocorticoid prophylaxis against acute mountain sickness. Hormone and Metabolic Research2002;34(6):318‐24. [PUBMED: 12173072] ">Basu 2002b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0009" title="BatesMG , ThompsonAA , BaillieJK , SutherlandAI , IrvingJB , HiraniN , et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo‐controlled trial. High Altitude Medicine &amp; Biology2011;12(3):207‐14. [PUBMED: 21962063] ">Bates 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0010" title="BaumgartnerRW , KellerS , RegardM , BartschP . Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m. High Altitude Medicine &amp; Biology2003;4(3):333‐9. [PUBMED: 14561238] ">Baumgartner 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ=AMS‐C SCORE&gt;0,70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0011" title="BernhardWN , MillerSL , GittelsohnA . Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. Journal of Wilderness Medicine1994;5(3):331‐8. ">Bernhard 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% subjects with previous AMS mild or moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5334</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= 3 cerebral symptoms, one with intensity ≥2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0012" title="BernhardWN , SchalickLM , DelaneyPA , BernhardTM , BarnasGM . Acetazolamide plus low‐dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviation, Space, and Environmental Medicine1998;69(9):883‐6. [PUBMED: 9737760] ">Bernhard 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of the subjects had previously visited high altitudes and had experienced mild to moderate AMS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5334</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= 3 cerebral symptoms, one with intensity ≥2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0013" title="BradwellAR , DykesPW , CooteJH , ForsterPJ , MillesJJ , ChesnerI , et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet1986;1(8488):1001‐5. [PUBMED: 2871285] ">Bradwell 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4846</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0014" title="BurkiNK , KhanSA , HameedMA . The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest1992;101(3):736‐41. [PUBMED: 1541140] ">Burki 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4450</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0016" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM , PühringerR , LämmleT . Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache2001;41(6):542‐5. ">Burtscher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3480</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache scoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0017" title="BurtscherM , GattererH , FaulhaberM , BurtscherJ . Acetazolamide pre‐treatment before ascending to high altitudes: When to start?. International Journal of Clinical and Experimental Medicine2014;15(11):4378‐83. [PUBMED: 25550957] ">Burtscher 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of AMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3800</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than a day by car up to 3480, and 2.8 to 3 hours climbing from there to 3800m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0015" title="BurtscherM , LikarR , NachbauerW , PhiladelphyM . Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ1998;316(7137):1057‐8. ">Burtscher 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3480</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache scoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0018" title="CarlstenC , SwensonER , RuossS . A dose‐response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Altitude Medicine &amp; Biology2004;5(1):33‐9. [PUBMED: 15072715] ">Carlsten 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3630</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0019" title="ChenGZ , ZhengCR , QinJ , YuJ , WangH , ZhangJH , et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. Journal of Emergency Medicine2015;48(2):197‐206. [PUBMED: 25294611] XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;16 Suppl 1(64):C69. ">Chen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3700</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0020" title="ChowT , BrowneV , HeilesonHL , WallaceD , AnholmJ , GreenSM . Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo‐controlled trial. Archives of Internal Medicine2005;165(3):296‐301. [PUBMED: 15710792] ">Chow 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3800</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0021" title="EllsworthAJ , MeyerEF , LarsonEB . Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. Western Journal of Medicine1991;154(3):289‐93. [PUBMED: 2028586] ">Ellsworth 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4392</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0022" title="FaullOK , RobertsonJ , ThomasO , BradwellAR , AntoniadesCA , PattinsonKTS , et al. The effect of acetazolamide on saccadic latency at 3459 meters. Wilderness and Environmental Medicine2015;26(1):72‐7. ">Faull 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3459</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0023" title="FischerR , HautmannH , ToepferM , TschoepM , PongratzH , HuberRM . Oral slow release theophylline (oT) is effective in prevention of acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1998;12(Suppl 28):407S. [CN‐00382822] FischerR , LangSM , SteinerU , ToepferM , HautmannH , PongratzH , et al. Theophylline improves acute mountain sickness. European Respiratory Journal2000;15(1):123‐7. [PUBMED: 10678632] ">Fischer 2000a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0024" title="">Fischer 2000b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0025" title="FischerR , VollmarC , ThiereM , BornC , LeitlM , PflugerT , et al. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia2004;24(1):66‐71. [PUBMED: 14687016] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ‐C score &gt;0,5 or Lake Louise AMS score&gt;3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0026" title="FulcoCS , MuzaSR , DitzlerD , LammiE , LewisSF , CymermanA . Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude. Clinical Science2006;110(6):683‐92. [PUBMED: 16499476] ">Fulco 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0027" title="GreeneMK , KerrAM , McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness: a double‐blind controlled cross‐over study. BMJ1981;283(6295):811‐3. [PUBMED: 6794709] ">Greene 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5895</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0028" title="HackettPH , RennieD , LevineHD . The incidence, importance, and prophylaxis of acute mountain sickness. Lancet1976;2(7996):1149‐55. [PUBMED: 62991] ">Hackett 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4243</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire clinical&gt;2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0029" title="HackettPH , RoachRC , WoodRA , FoutchRG , MeehanRT , RennieD , et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine1988;59(10):950‐4. [PUBMED: 3190622] ">Hackett 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4400</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS Score&gt;2 or Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0030" title="GertschJH , LipmanGS , HolckPS , MerrittA , MulcahyA , FisherRS , et al. Prospective, double‐blind, randomized, placebo‐controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness &amp; Environmental Medicine2010;21(3):236‐43. [PUBMED: 20832701] ">HEAT 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0031" title="HillenbrandP , PahariAK , SoonY , SubediD , BajracharyaR , GurungP , et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double‐blind controlled trial. Wilderness &amp; Environmental Medicine2006;17(2):87‐93. [PUBMED: 16805144] ">Hillenbrand 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4930</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0032" title="HochapfelG , SchlemmerW . Prophylaxis of acute mountain sickness. Experiences with acetazolamide in Nepal. Munchener Medizinische Wochenschrift1986;128(8):137‐8. ">Hochapfel 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61,00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0033" title="HohenhausE , GoerreS , NiroomandF , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness [abstract]. European Respiratory Journal. Supplement.1993; Vol. 7 Suppl 17:187S. [CN‐00393692] HohenhausE , NiroomandF , GoerreS , VockP , OelzO , BartschP . Nifedipine does not prevent acute mountain sickness. American Journal of Respiratory and Critical Care Medicine1994;150(3):857‐60. [PUBMED: 8087361] ">Hohenhaus 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86,00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>susceptibility to AMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Score clinical proposed at the International Hypoxia symposium+ Do you feel ill?=Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0034" title="HussainMM , AslamM , KhanZ . Acute mountain sickness score and hypoxemia. Journal of the Pakistan Medical Association2001;5(5):173‐9. ">Hussain 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4578</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ score &gt; = 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0035" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3500</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0036" title="JohnsonTS , RockPB , FulcoCS , TradLA , SparkRF , MaherJT . Prevention of acute mountain sickness by dexamethasone. New England Journal of Medicine1984;310(11):683‐6. [PUBMED: 6700643] ">Johnson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0037" title="KayserB , HulseboschR , BoschF . Low‐dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(1):15‐23. [PUBMED: 18331216] ">Kayser 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5896</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0038" title="KeT , WangJ , SwensonER , ZhangX , HuY , ChenY , et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Altitude Medicine &amp; Biology2013;14(2):162‐7. [PUBMED: 23795737] ">Ke 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of of headache and at least one of the symptoms of nausea or vomiting, fatigue, dizziness, or difficulty sleeping, and a total score of at least 3, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0039" title="KüpperTE , StrohlKP , HoeferM , GieselerU , NetzerCM , NetzerNC . Low‐dose theophylline reduces symptoms of acute mountain sickness. Journal of Travel Medicine2008;15(5):307‐14. [PUBMED: 19006503] ">Küpper 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0040" title="LarsonEB , RoachRC , SchoeneRB , HornbeinTF . Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA1982;248(3):328‐32. [PUBMED: 7045433] ">Larson 1982a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4394</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAQ = Headache moderate or more and/or nausea moderate or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0041" title="">Larson 1982b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4394</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAQ = Headache moderate or more and/or nausea moderate or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0042" title="LipmanGS , KanaanNC , HolckP , GertschJH , ConstanceBB , CorbettB , et al. Ibuprofen prevents altitude illness: A prospective, double‐blind, randomized controlled trial. Academic Emergency Medicine2011;18(5 Suppl 1):S15. LipmanGS , KanaanNC , HolckPS , ConstanceBB , GertschJH , PAINS Group. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti‐inflammatories. Annals of Emergency Medicine2012;58(6):484‐90. [PUBMED: 22440488] ">Lipman 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3810</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0043" title="LuksAM , HendersonWR , SwensonER . Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Altitude Medicine &amp; Biology2007;8(2):131‐8. [PUBMED: 17584007] ">Luks 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3900</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0044" title="BernheimAM , KienckeS , FischlerM , DorschnerL , DebrunnerJ , MairbaurlH , et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest2007;132:380‐7. FischlerM , MaggioriniM , DorschnerL , DebrunnerJ , BernheimA , KienckeS , et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high‐altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine2009;180(4):346‐52. [PUBMED: 19520908] MaggioriniM , Brunner‐La RoccaHP , PethS , FischlerM , BohmT , BernheimA , et al. Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine2006;145(7):497‐506. [PUBMED: 17015867] MairbaurlH , Brunner‐La RoccaHP , PethS , DehnertC , FischlerM , BohmT , et al. Phosphodiesterase‐5 inhibitors and glucocorticoids prevent a high‐altitude pulmonary oedema. Deutsche Zeitschrift für Sportmedizin2005; Vol. 56, issue 7/8:218. [CN‐00727391] ">Maggiorini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>History of HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0045" title="MirrakhimovM , BrimkulovN , CielickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Asthma treatment at high altitude effects of acetazolamide on overnight oximetry and prevention of acute mountain sickness [Abstract]. European Respiratory Journal1992; Vol. 5, issue Suppl 15:366s. [CN‐00494881] MirrakhlmovM , BrimkulovN , CieslickiJ , TobiaszM , KudaiberdievZ , MoldotashevI , et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. European Respiratory Journal1993;6(4):536‐40. [PUBMED: 8491304] ">Mirrakhlmov 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kirguistán</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3200</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0046" title="MontgomeryAB , LuceJM , MichaelP , MillsJ . Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA1989;261(5):734‐6. [PUBMED: 2911170] ">Montgomery 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS score clinical= 3 or more symptoms with a grade 2 or greater</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0047" title="MoragaFA , FloresA , SerraJ , EsnaolaC , BarrientoC . Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness &amp; Environmental Medicine2007;18(4):251‐7. [PUBMED: 18076292] ">Moraga 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Cable‐cars or train)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3696</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,5 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMS score clinical≥3 or 1 symptom=3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0048" title="MuzaSR , KaminskyD , FulcoCS , BanderetLE , CymermanA . Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviation, Space, and Environmental Medicine2004;75(5):413‐9. [PUBMED: 15152893] ">Muza 2004</a> Def1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0049" title="BasnyatB , GertschJH , HolckPS , JohnsonEW , LuksAM , DonhamBP , et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Altitude Medicine &amp; Biology2006;7(1):17‐27. [PUBMED: 16544963] ">PACE 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 to 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0050" title="CaravitaS , FainiA , LombardiC , ValentiniM , GregoriniF , RossiJ , et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest2015;147(1):120‐31. ParatiG , ReveraM , GiulianoA , FainiA , BiloG , GregoriniF , et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. European Heart Journal2013;10(10):759‐66. SalviP , ReveraM , FainiA , GiulianoA , GregoriniF , Agostoni , et al. Changes in subendocardial viability ratio with acute high‐altitude exposure and protective role of acetazolamide. Hypertension2013;61(4):793‐9. ">Parati 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;28 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0051" title="GertschJH , BasnyatB , JohnsonEW , OnopaJ , HolckPS . Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ2004;328(7443):797. [PUBMED: 15070635] ">PHAIT 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 to 74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4928</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0052" title="RockPB , JohnsonTS , CymermanA , BurseRL , FalkLJ , FulcoCS . Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation, Space,and Environmental Medicine1987;58(7):668‐72. [PUBMED: 3619842] ">Rock 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified ESQ= AMS‐C&gt;0,7 + AMS‐R&gt;0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0053" title="RockPB , JohnsonTS , LarsenRF , FulcoCS , TradLA , CymermanA . Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest1989;95(3):568‐73. [PUBMED: 2920585] ">Rock 1989a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0054" title="">Rock 1989b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0055" title="">Rock 1989c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson Score≥1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0056" title="SartoriC , AllemannY , DuplainH , LeporiM , EgliM , LippE , et al. Salmeterol for the prevention of high‐altitude pulmonary edema. New England Journal of Medicine2002;346(21):1631‐6. [PUBMED: 12023995] ">Sartori 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>susceptible to HAPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4559</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0057" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 hours‐4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score= headache + 1 symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0058" title="JulianCG , SubudhiAW , WilsonMJ , DimmenAC , PechaT , RoachRC . Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. Journal of Applied Physiology2011;111(2):392‐9. SubudhiAW , DimmenAC , JulianCG , WilsonMJ , PaneraiRB , RoachRC . Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. Journal of Applied Physiology2011;110(5):1219‐25. [PUBMED: 21393464] ">Subudhi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No applicable</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4875</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0059" title="VanPatotMC , LeadbetterG3rd , KeyesLE , MaakestadKM , OlsonS , HackettPH . Prophylactic low‐dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Medicine &amp; Biology2008;9(4):289‐93. [PUBMED: 19115912] ">Van Patot 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 to 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4300</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESQ AMS‐C Score≥0,7 + Lake Louise AMS score≥3 with headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0060" title="WangJ , KeT , ZhangX , ChenY , LiuM , ChenJ , et al. Effects of acetazolamide on cognitive performance during high‐altitude exposure. Neurotoxicology and Teratology2013;35:28‐33. [PUBMED: 23280141] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolivia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Flight)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3561</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0061" title="WrightAD , BradwellAR , FletcherRF . Methazolamide and acetazolamide in acute mountain sickness. Aviation, Space, and Environmental Medicine1983;54(7):619‐21. [PUBMED: 6349608] ">Wright 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous severe AMS= 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4790</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0062" title="WrightAD , BeazleyMF , BradwellAR , ChesnerIM , ClaytonRN , ForsterPJ , et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness &amp; Environmental Medicine2004;15(1):25‐31. [PUBMED: 15040503] ">Wright 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4680</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lake Louise AMS score≥3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0063" title="ZellSC , GoodmanPH . Acetazolamide and dexamethasone in the prevention of acute mountain sickness. Western Journal of Medicine1988;148(5):541‐5. [PUBMED: 3051673] ">Zell 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (combination)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4050</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition was provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009761-bbs2-0064" title="ZhengCR , ChenGZ , YuJ , QinJ , SongP , BianSZ , et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. American Journal of Medicine2014;127(10):1001‐9.e2. [PUBMED: 24784698] ">Zheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No (Car)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3900</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LLS includes 5 self‐reporting symptoms:headache, gastrointestinal symptoms, fatigue/weakness, dizziness/lightheadedness and difficulty in sleeping. Each symptom is scores 0‐3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/full#CD009761-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carbonic anhydrase inhibitors: acetazolamide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of acute mountain sickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.39, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Acetazolamide 250 ‐ 255 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Acetazolamide 500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.38, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Acetazolamide 750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.18, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Other combinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of high altitude pulmonary oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of high altitude cerebral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of adverse events: Paraesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.53 [2.81, 10.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Acetazolamide 250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.63 [4.02, 39.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Acetazolamide 500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.72 [3.94, 11.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Acetazolamide 750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [2.00, 4.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Differences in HAI/AMS scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 acetazolamide 250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 acetazolamide 500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.20, 0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carbonic anhydrase inhibitors: acetazolamide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Steroids: budesonide vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of acute mountain sickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Steroids: budesonide vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Steroids: dexamethasone vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of acute mountain sickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Differences in HAI/AMS scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.21, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Steroids: dexamethasone vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium modulators: nifedipine vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Differences in HAI/AMS scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.85, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium modulators: nifedipine vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NSAIDs and other analgesic: aspirin vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of AMS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.06, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NSAIDs and other analgesic: aspirin vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009761-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NSAIDs and other analgesic: ibuprofen vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of acute mountain sickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.49, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NSAIDs and other analgesic: ibuprofen vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009761.pub2/references#CD009761-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009761.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009761-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009761-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009761-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD009761-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009761-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009761-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009761-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009761\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009761\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009761\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009761\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009761\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009761.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009761.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009761.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009761.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009761.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719314909"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009761.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719314912"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009761.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de5bb5d239368',t:'MTc0MDcxOTMxNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 